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publicised.	 These	 issues,	 in	 combination	 with	 a	 growing	 global	 reliance	 upon	
antibiotics	 for	 everyday	 modern	 life,	 urgently	 require	 the	 discovery	 of	 novel	
antibacterial	drugs.	
Endolysins	 are	 one	 potential	 candidate	 to	 support,	 or	 replace,	 conventional	










This	 study	 initially	 focuses	 upon	 improving	 the	 accumulation	 and	 activity	 of	 one	
endolysin,	Cpl-1,	targeting	Streptococcus	pneumoniae.	Recombinant	Cpl-1	has	been	
shown	 previously	 in	 the	 Purton	 lab	 to	 accumulate	 to	 moderate	 levels	 in	 the	 C.	
reinhardtii	 chloroplast.	Here	we	present	 two	 transgenic	 lines	of	C.	 reinhardtii	 that	
appear	 to	 accumulate	 recombinant	 Cpl-1	 to	 higher	 levels	 –	 one	 through	 the	
incorporation	 of	 multiple	 expression	 cassettes,	 and	 one	 through	 codon	 pair	









aadA	 	 	 aminoglycoside-3’’-adenyl-transferase	gene	
Amp	 	 	 ampicillin	
AMPS		 	 	 ammonium	persulphate		
BHI	 	 	 brain	heart	infusion	
BME	 	 	 β-mercaptoethanol	
bp	 	 	 base	pairs	
BSA	 	 	 bovine	serum	albumin	
CBD	 	 	 cell	binding	domain	
CD	 	 	 catalytic	domain	
CES	 	 	 control	by	epistasis	of	synthesis	
CFU	 	 	 colony	forming	unit	
CPK	 	 	 Corey,	Pauling,	Koltun		
CTB	 	 	 cholera	toxin	B	
DNA		 	 	 deoxyribonucleic	acid		
dNTP		 	 	 2’deoxynucleoside	5’-triphosphate		
EDTA		 	 	 ethylenediaminetetraacetic	acid	(disodium	salt)		
e.	g.		 	 	 exempli	gratia	=	for	example	
ELISA	 	 	 enzyme-linked	immunosorbent	assay	
g	 	 	 gram	
GC	 	 	 guanine	and	cytosine	
GFP	 	 	 green	fluorescent	protein	
GOI	 	 	 gene	of	interest	
HA	 	 	 hemagglutinin	
		 7	
His	 	 	 histidine	
HSM	 	 	 high	salt	minimal	medium	
IPTG	 	 	 Isopropyl	β-D-1-thiogalactopyranoside	
kb	 	 	 kilo	base	pairs	
kDa	 	 	 kilo	Dalton	
LB	 	 	 luria-bertani	medium	
mg	 	 	 milligram	
min	 	 	 minute	
ml	 	 	 millilitre	
mM	 	 	 milimolar	
mRNA			 	 messenger	ribonucleic	acid		
mt	 	 	 mating-type	
NCBI		 	 	 National	Centre	for	Biotechnology	Information		
OD		 	 	 optical	density		
ORF		 	 	 open	reading	frame		
PCR		 	 	 polymerase	chain	reaction		
PDB	 	 	 protein	data	bank	
PEG		 	 	 polyethylene	glycol		
PG	 	 	 peptidoglycan	
PMF	 	 	 proton	motive	force	
PSI	 	 	 photosystem	I	
PSII	 	 	 photosystem	II	
psi	 	 	 pounds	per	square	inch	
RCSB	 	 	 Research	Collaboratory	for	Structural	Bioinformatics	
		 8	
RNA		 	 	 ribonucleic	acid		
rRNA		 	 	 ribosomal	ribonucleic	acid		
SD	 	 	 Shine-Dalgarno	consensus	sequence	
SDS		 	 	 sodium	dodecyl	sulphate		
SDS-PAGE		 	 sodium	dodecyl	sulphate	polyacrylamide	gel	electrophoresis		
STGG	 	 	 skimmed	milk	tryptone	glycerol	glucose	medium	
Strep	 	 	 streptavidin	 	 	
TAP	 	 	 tris	acetate	phosphate	medium	
TBS	 	 	 tris	buffered	saline	
TBS-T	 	 	 tris	buffered	saline	–	tween	20	
TCP	 	 	 total	cell	protein	
TEMED		 	 N,	N,	N’,	N’-tetramethylethylenediamine		
tris		 	 	 tris	(hydroxymethyl)	aminomethane		
TRA	 	 	 turbidity	reduction	assay	
tRNA		 	 	 transfer	ribonucleic	acid		
TSP		 	 	 total	soluble	protein		
TSY	 	 	 trypticase	soy	yeast	extract	medium	
UTR		 	 	 untranslated	region		
v/v		 	 	 volume	for	volume		
w/v		 	 	 weight	for	volume		
WGS	 	 	 whole	genome	sequencing	
WHO	 	 	 World	Health	Organisation	



































































































































































across	 the	 globe.	 After	 the	 initial	 discovery	 of	 penicillin	 by	 Fleming	 at	 St	 Mary’s	
Hospital	 in	 London,	 it	 took	 a	 further	 16	 years	 of	 refinement,	 optimization	 and	
collaboration	between	industry	and	academia	before	penicillin	could	be	produced	in	

















antibiotics,	 benzylpenicillin	 functions	 through	disrupting	 cell	wall	 biosynthesis	 in	bacteria.	
The	 image	 on	 the	 right	 shows	 benzylpenicilin	 inhibiting	 formation	 of	 crosslinks	 in	 the	
bacterial	 peptidoglycan	 cell	 wall.	 Normally	 transpeptidases	 (also	 called	 penicilin-binding	
proteins)	 bind	 to	 D-alanyl-D-alanine	 pentapeptide	 of	 the	 peptidoglycan	 monomers	 and	






discovery	 (Arias	 and	Murray	 2015).	 These	 small	molecules	were	 all	 isolated	 from	





role,	these	identified	 	antibiotics	 targeted	 several	 different	 aspects	 of	 bacterial	
machinery	essential	for	cell	maintenance	and	reproduction,	an	illustration	of	which	



























This	 stems	 from	 the	 discovery	 that	 sub-therapeutic	 levels	 of	 antibiotic	 cause	
increased	growth.	The	mechanism	for	this	remains	unclear,	but	the	most	likely	theory	
seems	 to	 be	 that	 growth	 is	 more	 efficient	 without	 gut	 bacteria	 competing	 for	
nutrients	(Gaskins	et	al.	2002).	Not	only	do	low	levels	of	antibiotics	improve	growth	
rates,	 but	 also	 conception	 rates	 and	 feed	 conversion	 ratios,	 altogether	 having	 a	
pronounced	impact	upon	global	meat	production	(Hao	et	al.	2014).	





aquaculture	 to	 industrial	 scales	 has	 been	 almost	wholly	 reliant	 upon	prophylactic	
antibiotic	use,	enabling	the	high	density	farming	of	fish	to	meet	the	growing	global	
demand	(Cabello	2006).	
The	 remarkable	 reliance	 that	 the	 modern	 world	 has	 built	 upon	 antibiotic	
consumption	 leads	 us	 to	 worry	 about	 what	 would	 happen	 if	 they	 ceased	 to	 be	
effective.	We	have	mentioned	briefly	just	a	few	of	the	huge	industries	that	use,	and	
over-use,	antibiotics.	As	we	will	see	in	the	following	section,	antibiotics	are	a	finite	

















the	 same	 year	 as	 it	 was	 introduced	 (Ventola	 2015).	 It	 is	 therefore	 important	 to	




























categories	 for	 resistance	 can	 be	 formed:	 endogenous	 resistance	 and	 exogenous	
resistance.	 Endogenous	 resistance	 refers	 to	 resistance	 arising	 within	 the	 bacteria	
itself	 i.e.	 by	mutation	and	 selection.	 Exogenous	 resistance	 involves	 the	passing	of	
resistance	 genes	 between	 different	 bacterial	 species	 via	 horizontal	 gene	 transfer	
(Silver	2011),	each	of	which	is	explored	below.	
Endogenous	resistance	is	often	genetically	recessive	as	it	tends	to	result	in	a	loss	of	





Exogenously	 acquired	 resistance	 on	 the	 other	 hand	 generally	 involves	 a	 gain	 of	
function	and	is	therefore	more	stable,	for	example	the	ability	to	synthesize	antibiotic-
degrading	enzymes.	Apart	from	a	slight	metabolic	burden,	these	gains	of	function	are	




resistance	 to	 be	 selected.	 For	 example,	 the	 lack	 of	 distinction	 between	 “human	
antibiotics”	 and	 “veterinary	 antibiotics”	 has	 dangerous	 implications	 for	 emerging	
resistance	via	horizontal	gene	transfer.	Furthermore,	the	manner	in	which	antibiotics	
are	generally	delivered	to	livestock,	such	as	in	their	food	or	water,	can	lead	to	sub-

















This	alarming	drop-off	 in	antibiotic	discovery	 is	due	to	several	 factors.	 In	the	early	
days	of	antibiotic	research,	discovery	was	largely	through	empirical	screening	–	this	
amounted	 to	 testing	 of	 various	 microorganism	 extracts	 for	 bacterial	 growth	
inhibition,	 requiring	 little	 understanding	 of	 their	 action.	 This	 method	 worked	
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extremely	well	in	the	1940s,	50s	and	60s,	but	soon	these	“low	hanging	fruits”	had	all	
been	 discovered.	 These	 methods	 soon	 led	 to	 replication	 of	 discovery;	 common	
antibiotics	 were	 being	 repeatedly	 discovered,	 thus	 reducing	 the	 efficiency	 of	 the	
discovery	system.	The	method	deployed	shifted	towards	target-directed	screens	and	
eventually	 big	 pharma	 companies	 reallocated	 resources	 to	 more	 lucrative	
therapeutics	(Livermore	2011;	Silver	2011).	Economically,	the	antibiotic	market	has	
been	 somewhat	 a	 victim	 of	 its	 own	 success:	 with	many	 competing	 drugs	 on	 the	
market,	 the	 price	 pharmaceutical	 companies	 can	 charge	 per	 prescription	 of	
antibiotics	is	much	lower	than	that	of	many	other	drugs	(Bax	1997).	
However,	 the	 news	 is	 not	 all	 bad.	 Although	 no	 (or	 few)	 new	 classes	 have	 been	
discovered	 since	 the	 1980s,	 there	 have	 been	 improvements	 within	 the	 existing	
classes.	While	such	modifications	do	increase	the	efficacy	of	these	antibiotics	for	a	




lactam	 antibiotics.	 But	 none	 of	 these	 techniques	 broaden	 the	 limited	 number	 of	
targets	that	our	antibiotic	arsenal	currently	possesses	and	have	been	incremental	in	
nature.		





example	 colistin	 acts	 as	 a	 highly	 synergistic	 combination	 with	 several	 other	
antibiotics,	by	improving	the	permeability	of	the	bacterial	outer	membrane	in	Gram	
negative	bacteria	(Tängdén	et	al.	2014).	
One	of	 the	greatest	 restraints	 to	 the	“Golden	Era”	of	antibiotic	discovery	was	 the	
limited	number	of	microbes	that	could	be	grown	in	the	laboratory,	and	then	tested	






























resources,	 either	 by	 the	 introduction	 of	 other	 bacteria	 (probiotics)	 or	 the	
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sequestration	 of	 host	 nutrients	 (Spellberg	 2014).	 Furthermore,	 bacterial	 toxin	
inhibitors	and	biofilm	inhibitors	which	do	not	directly	harm	the	bacteria,	but	reduce	
their	pathogenicity	offer	a	promising	alternative	path.	A	major	advantage	of	these,	
along	with	host-response	modulation,	 is	 that	 they	do	not	apply	 the	 same	 level	of	




bacteria	 and	 therefore	 may	 offer	 a	 mechanism	 for	 active	 control	 of	 bacterial	
infections.	These	bacteria	go	one	step	 further	 than	commensal	 ‘probiotics’,	which	
generally	 compete	 for	 nutrients	 and	 resources	 thus	 reducing	 the	 scope	 for	
opportunistic	 pathogenic	 bacterial	 colonisation,	 by	 entering	 host	 bacteria	 and	
causing	 cell	 lysis	 (Dwidar	 et	 al.	 2012).	 Predatory	 bacteria,	 widely	 known	 as	










However,	 safety	 concerns	 around	 inoculating	 humans	 with	 bacteria	 must	 be	
addressed.	 A	 potentially	 toxic	 response	 to	 the	 lipopolysaccharides	 in	 the	 Gram-
negative	 outer-membrane	 of	 BALOs	 is	 yet	 to	 be	 solved.	 Furthermore,	 predatory	
bacteria	are	unable	to	eradicate	all	their	prey,	even	when	applied	in	very	high	ratios	
(Sockett	and	Lambert	2004),	and	are	also	strictly	aerobic	thus	limiting	their	potential	







shown	 to	 act	 independently	 as	 antimicrobials,	 but	 also	 to	 have	 wide	 ranging	
immunomodulatory	 functions	 in	 mammals,	 including	 altering	 gene	 expression,	




chronic	diseases	 and	are	 therefore	an	 interesting	 route	of	 research.	 The	mode	of	









Antimicrobial	peptides	 from	prokaryotes	are	known	as	 “bacteriocins”	and	 tend	 to	
have	a	narrower	activity	 spectrum.	Bacteriocins	have	been	used	 for	 some	 time	 in	
food	preservatives	–	for	example	nisin	is	used	to	treat	cheese,	meat	and	vegetables	
to	 improve	 shelf	 life	 (Yang	 et	 al.	 2014).	While	 effective	 as	 inhibitors	 of	microbial	










much	 of	 the	 globe	 after	 the	 discovery	 of	 penicillin.	 However,	 phage	 therapy	
continued	to	be	practiced	 in	 the	USSR	due	to	 their	 limited	access	 to	conventional	
antibiotics,	and	even	today	the	Eliava	 Institute	 in	Georgia	still	 treats	patients	with	
phage	therapy	(Fernebro	2011).	








Figure	 1.5	 The	 bacteriophage	 lytic	 cycle.	 Phage	 specifically	 bind	 to	 their	 target	 bacterial	







with	 Listeria	monocytogenes	 (Fernebro	 2011).	However,	 no	 FDA	 approval	 has	 yet	
been	made	for	human	therapies,	although	a	recent	“emergency	investigational	new	
drug	application”	was	 approved	 for	 the	 treatment	of	 a	patient	 in	 San	Diego,	USA	
suffering	 from	 a	 multi-drug	 resistance	 bacterial	 infection,	 which	 resulted	 in	 the	
successful	treatment	of	that	patient	(LaFee	and	Buschman	2017).	
The	high	specificity	of	bacteriophage	results	in	a	narrow-spectrum	of	activity.	This	is	
excellent	news	 for	 the	protection	of	 commensal	 flora	 in	 the	gut	 for	example,	but	
relies	on	 rapid	and	effective	diagnosis	 techniques	which	are	not	 readily	 available.	
Furthermore,	occurrence	of	resistance	to	phage	is	high,	and	poor	data	exist	on	the	
efficacy	 of	 treatment	 and	 their	 safety	 profile	 (Fernebro	 2011).	 However,	 if	 these	




their	 endolysins.	 These	 are	 the	 lytic	 enzymes	 which	 degrade	 the	 host	 bacterial	
peptidoglycan	cell	wall	during	cell	lysis.	The	use	of	these	proteins	as	novel	antibiotics	










by	 bacteria	 to	 attack	 competing	 bacteria	 of	 another	 species;	 lysozymes	 can	 be	
produced	 by	 eukaryotes	 as	 part	 of	 their	 innate	 immune	 response;	 tail-associated	











those	 from	Gram-positive	 infecting	bacteriophage,	and	 those	 from	Gram-negative	
infecting	bacteriophage.	Endolysins	targeting	Gram-positive	bacteria	have	a	modular	
structure	 and	 are	highly	 species	 specific.	 Their	modular	 structure	 consists	 of	 a	N-
terminal	catalytic	domain	and	a	C-terminal	cell	wall	binding	domain	(CBD),	generally	
connected	by	a	flexible	acidic	linker	(Figure	1.6).	The	majority	of	endolysin	specificity	
is	 conferred	by	 the	cell	wall	binding	domain,	although	 in	 some	cases	 the	catalytic	















Gram-negative	 endolysins	 on	 the	 other	 hand	 tend	 to	 be	 smaller	 with	 a	 globular	
structure,	and	lack	the	high	binding	affinity	and	specificity	for	the	cell	wall.	The	reason	
for	 this	 is	 believed	 to	 be	 that,	 while	 it	 may	 be	 advantageous	 for	 Gram-positive	
targeting	endolysins	to	bind	tightly	to	the	peptidoglycan	cell	wall	in	order	to	prevent	
them	 from	 lysing	 surrounding	 bacteria	 which	might	 be	 future	 hosts	 for	 the	 viral	

























β-D-muramidase;	B:	 N-acetyl-β-D-glucosaminidase).	 Green	 arrows	 indicate	 endopeptidase	
targets	 (C:	 D-glutamyl-L-lysine	 endopeptidase;	 D:	 D-alanoyl-L-alanine	 endopeptidase).	
Modified	from	Schmelcher	et	al.	(2012).	
CBD	 domains	 are	 present	 in	 Gram-positive	 targeting	 endolysins,	 and	 recruit	 the	
catalytic	domain	to	the	peptidoglycan	cell	wall.	The	CBD	is	largely	responsible	for	the	
specificity	observed	in	endolysins	and	is	able	to	recognize	and	bind	(non-covalently)	
a	range	of	 ligands	 in	the	cell	wall.	These	 ligands	can	either	be	a	direct	part	of	 the	
peptidoglycan,	or	they	can	be	other	components	of	the	cell	wall.	An	example	of	the	
first	is	the	LysM	domain,	one	of	the	most	common	conserved	binding	modules,	which	

























Gram-positive	 bacteria,	 which	 have	 no	 outer	 membrane,	 are	 also	 susceptible	 to	
endolysins	 applied	 exogenously	 as	 the	 endolysin	 can	 directly	 access	 the	
peptidoglycan	 cell	 wall.	 The	 osmotic	 pressure	 inside	 the	 bacterial	 cell	 (20-50	




1.8)	 which	 prevents	 the	 endolysins	 from	 accessing	 the	 peptidoglycan	 layer	 when	
applied	exogenously.	However,	recent	advancements	have	opened	up	the	field	for	
endolysin	 therapy	 against	 Gram-negative	 bacterial	 infections.	 The	 addition	 of	 a	
polycationic	 peptide,	 able	 to	 cross	 the	 lipopolysaccharide	 outer-membrane,	 to	 a	




Figure	 1.8	 The	 cell	wall	 structural	 differences	 between	Gram-positive	 and	Gram-negative	
bacteria.	 The	 noticeable	 differences	 are	 the	 thicker	 peptidoglycan	 cell	 wall	 in	 the	 Gram-
postive	bacteria,	and	the	presence	of	an	outer	membrane	in	Gram-negative	bacteria.	In	both	
instances	 the	 cytoplasm	 is	 at	 the	bottom	of	 the	diagram.	Reproduced	 from	 (Brown	et	al.	
2015).	
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The	 first	 in	 vivo	 demonstration	 of	 endolysin	 activity	 was	 performed	 by	 Vincent	









GladSkin,	 has	 been	 approved	 for	 topical	 treatment	 of	 Staphylococcus	 aureus	 on	














expressed,	 soluble	 and	 readily	 purified	when	 produced	 in	 E.	 coli	 (Parmley	 2014).	
While	 this	 appears	 to	 have	 been	 a	 suitable	 approach	 for	 producing	 endolysins	
targeting	Gram-positive	bacteria,	it	is	unclear	whether	these	companies	will	seek	to	
use	 an	 alternative	 expression	 platform	 for	 producing	 endolysins	 targeting	 Gram-
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negative	bacteria.	Some	Gram-negative	targeting	endolysins	have	been	shown	to	be	
highly	 toxic	 to	E.	 coli,	 such	as	SPN9CC	 (Lim	et	al.	 2014),	 and	 therefore	potentially	
render	E.	coli	an	inefficient	production	platform.	
1.2.2.3 Advantages	of	endolysins	over	conventional	antibiotics	







to	 achieve	 similar	 levels	 of	 killing	 (Pastagia	 et	 al.	 2013).	Generally,	 endolysins	 act	
much	 faster	 than	conventional	antibiotics,	which	 for	blood	 infections	 in	particular	
such	as	sepsis	and	bacteraemia,	could	be	lifesaving.	
The	 specificity	 of	 endolysins	 presents	 an	 enormous	 advantage	 over	 conventional	
antibiotics	if	the	infecting	bacteria	has	been	diagnosed.	The	advantages	are	two-fold:	
firstly,	 a	 specific	antibiotic	will	not	disrupt	 the	body’s	 indigenous	 “good”	bacteria,	
while	killing	the	pathogen.	This	minimises	the	opportunity	for	secondary	infections	
such	 as	 Clostridium	 difficile	 infection	 and	 yeast	 infections	 which	 are	 common	
complications	 after	 a	 course	 of	 broad-spectrum	 antibiotics	 (U.S.	 Department	 of	
Health	and	Human	Services	2013).	Secondly,	as	the	vast	majority	of	bacteria	in	the	
body	or	environment	are	unaffected	by	the	endolysin,	no	selective	pressure	is	applied	






lining,	 to	 water	 treatment	 plant	 equipment.	 Bacterial	 cells	 in	 biofilms	 are	 in	 a	
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walls,	 regardless	 of	 the	 state	 of	 the	 cell	 and	 have	 been	 shown	 to	 be	 extremely	
effective	against	biofilms	(Gutiérrez	et	al.	2014).	
One	of	the	greatest	and	most	often	quoted	advantages	of	endolysins	is	that,	so	far,	
bacterial	 resistance	 to	 them	 has	 been	 unreported,	 despite	 efforts	 to	 produce	 it	
(Loeffler	 et	 al.	 2001).	 It	 is	 believed	 that	 several	 factors	 contribute	 to	 endolysin-
resistance	being	a	rare	event.	Firstly,	the	natural	evolution	of	endolysins	has	led	to	
the	adoption	of	highly	conserved	 targets	 in	 the	peptidoglycan	cell	wall,	which	are	
essential	for	bacterial	viability	(Fischetti	2008).	Secondly,	the	exogenous	application	
and	action	of	endolysins	avoids	many	of	the	resistance	mechanisms	observed	against	




will	 eventually	 be	 observed.	 In	 the	 case	 of	 conventional	 antibiotics,	 as	 we	 have	






them	 to	 remain	 active	 throughout	 the	 sewerage	 system	 and,	 eventually,	
watercourses	 too.	 These	 low	 levels	 of	 antibiotics	 in	 the	 environment	 create	 ideal	












more	bacterial	 autolysin	 activity	 (Daniel	 et	 al.	 2010).	 Such	 synergistic	 effects	may	
enable	 discontinued	 antibiotics	 to	 be	 reinstated	when	 used	with	 endolysins,	 and	
reduce	overall	antibiotic	intake	or	course	length.	
1.2.2.4 Limitations	
The	bacteria	posing	 the	greatest	 threat	 to	mankind	have	been	given	 the	acronym	
ESKAPE	 by	 the	 Infections	 Diseases	 Society	 of	 America,	 standing	 for	 Enterococcus	
faecium,	 Staphylococcus	 aureus,	 Klebsiella	 pneumoniae,	 Acinetobacter	 baumanni,	
Pseudomonas	aeruginosa,	and	Enterobacter	species	(Rice	2008).	Of	these,	the	final	

















host’s	 antibody	 mediated	 secondary	 immune	 response,	 and	 is	 thus	 largely	
unaffected.		
The	second	immune	response	of	concern	is	to	the	large	volume	of	bacterial	cell	debris	
rapidly	 released	 by	 endolysin	 activity.	 Two	 studies	 have	 been	 undertaken	 to	





dose	 is	 given,	 then	 the	 bacterial	 cell	wall	 is	 fragmented	 thus	 producing	 a	 greater	
response,	compared	to	a	low	dose	which	merely	punctures	the	bacterial	cells	with	
minimal	fragmentation	(Fischetti	2008).	
Bioavailability	 of	 endolysins	 is	 a	 concern	 given	 their	 large	 size	 compared	 to	
conventional	 antibiotics.	 In	 particular,	 intracellular	 bacterial	 infections	 such	 as	
chlamydia	and	tuberculosis	are	particularly	hard	to	access,	and	present	a	challenge	
even	for	conventional	antibiotics.	However,	a	recent	demonstration	that	PlyC	is	able	

























The	 remarkable	 ability	 of	 endolysins	 to	 identify	 and	 strongly	 bind	 highly	 specific	
bacterial	targets	has	produced	interest	in	fields	other	than	direct	therapeutics.	
For	example,	work	by	the	Loessner	group	at	ETH,	Zurich	has	used	endolysins	to	create	
rapid	 diagnostic	 tools	 for	 food	 safety.	 Their	 technology	 uses	 electrochemical	
impedance	 spectroscopy	 (EIS)	 to	 rapidly	detect	Listeria	 cells	 binding	 to	endolysin-
derived	CBDs	immobilized	on	a	gold	screen	printed	electrode.	This	enables	extremely	
rapid,	 accurate,	 and	 sensitive	 detection	 of	 contaminating	 Listeria	 cells	 in	 food	
products	(Tolba	et	al.	2012).		
Nelson’s	 group	 at	 the	University	 of	Maryland	 have	 designed	 two	 novel	 endolysin	
based	platforms,	designed	to	aid	the	body’s	natural	immune	system.	The	first	is	the	
generation	 of	 Infection	 Site	 Targeted	 Antitoxin	 antibodies	 (ISTAbs),	 which	 are	
endolysin	CBDs	fused	to	specific	antitoxin	neutralizing	monoclonal	antibodies.	The	
CBD	targets	the	antibody	to	the	pathogen	cell	wall,	where	it	sequesters	the	released	
toxins,	 thus	 reducing	 the	 toxin	 load	 and	 furthermore,	 functionally	 opsonises	 the	
bacterium	 for	 opsonophagocytic	 killing	 by	 the	 host	 immune	 system.	 The	 second	
approach,	named	Infection	Site	Targeted	universal	Bridging	Antigen	(ISTuBA),	fuses	
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2007).	 Since	 then,	 the	 ability	 to	 produce	 proteins	 recombinantly	 in	 a	 number	 of	
biological	 platforms	 has	 led	 to	 lower	 costs	 of	 production	 and	 the	 rise	 of	 protein	
therapies.	In	1977	Somatostatin,	a	very	small	inhibitor	peptide,	was	the	first	human	
recombinant	protein	to	be	produced	in	Escherichia	coli,	by	Genentech	Inc	(Brooker	
2010).	 Other	 platforms	 have	 since	 been	 developed	 to	 meet	 the	 various	 protein	
requirements,	 such	 as	 producing	 larger	 proteins,	 glycosylation	 patterns,	 and	















platform	 for	 current	 therapeutic	 proteins,	 in	 particular	 for	 the	 production	 of	
antibodies	 (Dumont	 et	 al.	 2015).	 As	 a	mammalian	 system,	 CHO	 cells	 are	 able	 to	
produce	 large	 proteins	 (over	 100	 kDa)	 and	 glycosylate	 and	 fold	 them	 correctly	 -	
although	 they	 do	 produce	 some	 post-translational	 modifications	 that	 are	 not	






platform,	 such	 as	 cheap	 growth	media	 and	 high	 yields,	 as	 well	 as	 advantages	 of	
mammalians	 cells,	 such	 as	 protein	 glycosylation	 and	 disulphide	 bond	 formation.	
Yeast	 therefore	 presents	 a	 very	 attractive	 platform	 for	 recombinant	 protein	
expression,	although	a	 few	 issues	prevent	 it	 from	being	using	 for	all	proteins.	For	
example,	yeast’s	high-mannose	 type	N-glycosylation	pattern	can	 lead	 to	a	 shorter	





including	 glycosylation.	 Either	 whole	 plants	 or	 plant	 cell	 cultures	 can	 be	 used	 as	
expression	 platforms.	 Both	 are	 devoid	 of	 the	 endotoxins	 and	 potential	 viral	






issues	 have	 limited	whole	 plant	 use	 to	 date,	 including	 the	 relatively	 long	 time	 to	
produce	 stable	 transgenic	 plants	 desired	 for	 long-term	 production,	 variable	
		 41	
expression	 levels,	and	 issues	of	biocontainment	at	 large	scale	 (Park	and	Wi	2016).	
Plant	cell	cultures	offer	solutions	to	many	of	these	issues,	such	precise	monitoring	
and	control	of	growth	conditions,	 consistent	 cell	 yields	and	biocontainment	when	
grown	in	bioreactors.	Several	plant	cell	lines	are	used	routinely,	such	as	those	derived	
from	N.	 tabacum,	 as	well	 as	 those	 from	edible	 crops	 including	 rice	 (Oriza	 sativa),	
carrot	(Daucus	carota)	and	tomato	(Lycopersicon	esculentum)	(Xu	and	Zhang	2014),	
and	 in	 2012	 taliglucerase	 alfa,	 the	 first	 plant-made	 pharmaceutical	 approved	 for	
human	use,	was	made	in	a	carrot	cell	line	to	treat	Gaucher’s	disease	(Grabowski	et	
al.	2014).		
Like	 plant	 cell	 cultures,	 microalgae	 offer	 many	 similar	 advantages	 over	 other	
platforms	 and	 higher	 plants,	 but	 have	 additional	 advantages	 too.	Microalgae	 are	
photosynthetic	 (unlike	carrot	cell	 cultures	 for	example),	enabling	 the	potential	 for	







The	 term	 microalgae	 can	 generally	 refer	 to	 any	 unicellular	 organism	 capable	 of	









(B)	 Merismopedia	 elegans	 (C)	 Acutodesmus	 acuminatus	 (D)	 Microcystis	 novacekii	 (E)	
Arthrospira	 jenneri	 (F)	 Dissodinium	 pseudolunula	 (G)	 Zygnema	 circumcarinatum	 (H)	
Actinocyclus	 normanii	 (I)	Pediastrum	duplex	 (J)	Klebsormidium	dissectum	 (K)	Diploneis	 (L)	














used	 as	 a	 model	 organism	 for	 many	 years	 for	 the	 investigation	 of	 the	 genetic	
mechanisms	behind	cellular	processes	(Harris	2009).	Microalgae	gained	prominence	
as	 a	 recombinant	 protein	 production	 platform	 with	 their	 potential	 to	 produce	
biofuels	without	 affecting	 food	 production	 -	 as	 a	 photosynthetic	 organism	 it	was	
postulated	that	algae	could	be	grown	in	areas	unsuitable	for	crop	production,	thus	
producing	 biomass	 from	 cheap	 substrates	 on	 unused	 land.	 However,	 despite	 the	








genetically	 engineered	 strains	 can	 be	 produced	 in	 a	matter	 of	weeks	 rather	 than	
sometimes	years	for	higher-plants;	and	scale	up	from	bench	to	production	scale	is	
straightforward	 (Franklin	 and	 Mayfield	 2004).	 Microalgae	 therefore	 present	 an	
extremely	attractive	platform	for	recombinant	protein	expression.		
Several	species	of	microalgae	have	to	date	been	genetically	transformed,	including	
C.	 reinhardtii,	Haematococcus	 pluvialis,	 Chlorella	 and	 diatoms	 (Spicer	 and	 Purton	
2016).	 H.	 pluvialis	 is	 a	 natural	 producer	 of	 astaxanthin,	 a	 carotenoid	 with	 high	
economic	 and	 health-related	 value,	 and	 it	 has	 been	 successfully	 genetically	
engineered	 to	 produce	 higher	 levels	 of	 astaxanthin	 (Steinbrenner	 and	 Sandmann	
2006).	The	green	alga	Chlorella	vulgaris	is	a	source	of	several	products	believed	to	be	





species	with	 the	most	 advanced	 genetic	 toolkit	 is	C.	 reinhardtii.	C.	 reinhardtii	 has	
been	 shown	 to	 express	 multiple	 recombinant	 proteins	 using	 a	 variety	 of	









diameter	 and	 has	 two	 flagella	 enabling	 phototaxis,	 and	 a	 large	 chloroplast	 filling	







the	 fact	 that	many	 nuclear	 genes	 are	 single	 copy	 (rather	 than	members	 of	 gene	
families)	 makes	 the	 recovery	 and	 classical	 genetic	 analysis	 of	 mutants	 very	
straightforward.	This	has	led	to	C.	reinhardtii	being	refered	to	as	the	“photosynthetic	
yeast”	 (Rochaix	1995).	Given	 these	attributes	and	 the	 fact	 that	 it	 is	 relatively	 fast	
growing	(5	-	8	hour	doubling	time,	depending	on	nutrient,	CO2	and	light	availability	















The	 nuclear	 genome	 can	 be	 transformed	 using	 a	 number	 of	 methods	 including	





play	an	 important	 role	 in	 gene	expression	 levels,	 improving	GFP	expression	 levels	
approximately	 5-fold	 (Fuhrmann	 et	 al.	 1999).	 However,	 gene	 silencing	 and	 low	
protein	 yields	 have	 been	 problematic	 for	 C.	 reinhardtii	 nuclear	 transformants,	
although	recent	work,	such	as	that	by	Barahimipour	et	al.	(2016)	demonstrating	high	
yields	 of	 HIV	 antigen	 P24,	 show	 that	 these	 issues	 are	 being	 gradually	 overcome.	
Furthermore,	 Lauersen	 et	 al.	 (2015)	 have	 created	 the	 pOptimized	 vector	 system,	
which	 allows	 the	 rapid	 swapping	 of	 reporter	 genes,	 selectable	 markers	 and	
regulatory	 elements	 to	 speed	 up	 the	 optimisation	 of	 nuclear	 protein	 expression,	
while	Scranton	et	al.	(2016)	have	demonstrated	the	successful	identification	and	use	
of	synthetic	nuclear	promoters	to	improve	heterologous	nuclear	gene	expression.		
The	 chloroplast	 on	 the	 other	 hand	 offers	 a	 more	 attractive	 target	 for	 genetic	
modification.	 Very	 simple	 transformation	 processes	 exist,	 for	 example	 transient	
pores	 can	 be	 formed	 by	 vortexing	 cell	 wall-less	mutants	 with	 glass	 beads,	 which	
enables	DNA	entry	to	the	chloroplast	(Kindle	et	al.	1991;	Maliga	2014).	Homologous	
recombination	 then	 allows	 precise	 targeting	 of	 expression	 cassettes	 into	 the	
plastome,	 and	 generally	 results	 in	 greater	 protein	 accumulation	 than	 nuclear	
transformations	(Franklin	et	al.	2002).	Furthermore,	by	transforming	photosynthesis-
deficient	 mutants,	 antibiotic-free	 selection	 is	 possible	 by	 using	 the	 rescue	 of	
photosynthesis	 as	 a	 selection	 mechanism	 (Wannathong	 et	 al.	 2016).	 The	 precise	









Figure	 1.11	 The	 nucleus	 and	 chloroplast	 genomes	 represent	 the	 major	 locations	 for	
transgene	 insertion	 and	 recombinant	 protein	 synthesis	 in	 C.	 reinhardtii.	 While	 the	
























(~70	%	TSP)	have	been	reported	 in	 the	chloroplast	of	Nicotiana	 (Oey	et	al.	2009).	








In	 fact,	 the	 two	companies	closest	 to	 therapeutic	endolysin	production	have	both	
been	 hampered	 by	 issues	 of	 product	 purity	 and	 solubility	 with	 their	 bacterial	
production	 systems.	ContraFect,	 attempting	 to	produce	an	endolysin	 for	 systemic	
use,	have	so	far	failed	to	receive	FDA	approval,	while	Micreos	have	instead	opted	to	
produce	 an	 endolysin	 for	 topical	 use,	 with	 less	 regulation	 around	 product	 purity	
(Parmley	2014).	
To	 date,	 the	major	 limitation	 to	microalgae	 as	 a	 recombinant	 protein	 production	
platform	has	been	their	low	production	yields.	CHO	cells	are	capable	of	producing	4-
6	 g/L	 of	 recombinant	 protein	 (Wurm	 2004),	 yeasts	 9-12	 g/L,	 E.	 coli	 15-17	 g/L,	
transgenic	animals	(e.g.	goat	milk)	up	to	23	g/L,	and	fungal	expression	systems	have	
been	 reported	 to	 achieve	 35	 g/L	 (Demain	 and	 Vaishnav	 2011).	 These	 are	 clearly	
optimized	 yields,	 and	 differ	 depending	 on	 the	 protein	 in	 question.	 However,	 the	
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highest	 level	 of	 recombinant	 protein	 production	 in	C.	 reinhardtii	 is	 5%	 TSP	 under	
laboratory	conditions	(Manuell	et	al.	2007),	which	would	equate	to	approximately	8	
mg/L	culture	volume	when	scaled	to	pilot	scale	 (Gimpel	et	al.	2015).	As	 it	 is,	pilot	
scale	 production	 of	 recombinant	 bovine	 milk	 amyloid	 A	 (MAA)	 in	 C.	 reinhardtii	
achieved	 3.28	 mg/L	 (Gimpel	 et	 al.	 2015).	 It	 is	 clear	 from	 these	 data	 that	 the	 C.	








but	 recovery	 rates	 and	 renaturation	 rates	 can	 be	 extremely	 low,	 leading	 to	 the	











Protein	 Function	 Use	 Reference	
HSV8-lsc	 Human	antibody	against	glycoprotein	D	from	Herpes	simplex	virus	 Therapeutic	 (Mayfield	et	al.	2003)	
CTB-VP1	 Protein	VP1	from	foot-and-mouth	disease	virus	fused	to	cholera	toxin	B	(CTB)	 Vaccine	 (Sun	et	al.	2003)	
hTRAIL Tumour	necrosis	factor-related	apoptosis-inducing	ligand	 Therapeutic	 (Yang	et	al.	2006)	
M-SAA	 Bovine	mammary-associated	serum	amyloid	 Therapeutic	 (Manuell	et	al.	2007)	
CSFV-E2 Swine fever virus structural protein E2 Vaccine (He et al. 2007) 
hGAD65	 Human	glutamic	acid	decarboxylase	 Diagnostics	 (Wang	et	al.	2008)	
VP28	 White	spot	syndrome	virus	protein	28	 Vaccine	 (Surzycki	et	al.	2009)	
CTB-D2	 D2	fibronectin-binding	domain	of	Staphylococcus	aureus	fused	to	CTB	 Vaccine	(oral)	 (Dreesen	et	al.	2010)	
VEGF	 Human	vascular	endothelial	growth	factor		 Therapeutic	 (Rasala	et	al.	2009)	
Pfs25	and	Pfs28	 Plasmodium	falciparum	surface	proteins	 Vaccine	(oral)	 (Gregory	et	al.	2012)	
αCD22PE40	 Antibody	against	DC22	surface	protein	from	B-cells	fused	to	two	domains	of	an	exotoxin	from	Pseudomonas	aeruginosa	 Immunotoxin	 (Tran	et	al.	2013)	
CtxB-Pfs25	 Plasmodium	falciparum	surface	protein	25	fused	to	CTB	 Vaccine	(oral)	 (Gregory	et	al.	2013)	
TPS4	 Bifunctional	diterpene	synthase,	for	therapeutic	terpenoid	synthesis	 Bioprocessing	 (Zedler	et	al.	2015)	
VHH	 Camelid	heavy	chain-only	antibodies	 Therapeutic	 (Markey	et	al.	2015)	
Ara	h	1	 Major	peanut	allergen	 Therapeutic	 (Gregory	et	al.	2016)	
Cpl-1	and	Pal	 Streptococcus	pneumoniae	targeting	endolysins	 Therapeutic	 (Stoffels	et	al.	2017)	







Although	 S.	 pneumoniae	 is	 a	 common	 commensal	 bacterium	 found	 in	 the	
nasopharynx,	and	 is	usually	benign,	colonisation	and	 infection	can	cause	a	host	of	
diseases,	 including	 pneumonia,	 meningitis,	 febrile	 bacteraemia	 and	 otitis	 media	








after	 its	 role	 in	 pneumonia.	 It	 usually	 takes	 a	 diplococcal	 form	 but	 can	 form	
streptococci	in	liquid	medium.	Depending	upon	the	strain,	a	polysaccharide	capsule	
sometimes	encases	the	cell,	below	which	is	the	peptidoglycan	cell	wall.	Presence	of	
this	 capsule	 can	 increase	 virility	 of	 the	 strain	 and	 interferes	 with	 leukocyte	





The	 peptidoglycan	 cell	 wall	 is	 approximately	 six	 layers	 thick	 and	 teichoic	 acid	 is	
attached	 to	 approximately	 every	 third	 N-acetylmuramic	 acid.	 Specifically	 to	 S.	
pneumoniae,	 both	 the	 teichoic	 acid	 and	 lipoteichoic	 acid	 (attached	 to	 the	 cell	
membrane	 via	 a	 lipid	 moiety)	 are	 decorated	 with	 phosphoryl-choline	 residues.	
Choline	 is	an	essential	 requirement	for	pneumococcal	activity,	being	the	 ligand	by	






also	 have	 an	 outer	 capsule,	 and	 both	 teichoic	 and	 lipoteichoic	 acids	 are	 decorated	 with	
choline.	Reproduced	from	Madigan	&	Martinko	(2006).	
While	 highly	 effective	 vaccines	 have	 been	 produced	 to	 protect	 humans	 from	 S.	
pneumoniae	infections,	their	success	has	been	limited	due	to	poor	coverage,	and	the	
threat	 of	 non-vaccine	 serotypes	 requires	 an	 active	 solution	 (Bogaert	 et	 al.	 2004).	
Studies	agree	that	prevention	of	nasopharyngeal	colonization	is	the	most	successful	
method	of	 averting	 infection,	however	 the	 rise	of	 antibiotic	 resistant	 strains	of	S.	
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pneumoniae,	in	particular	penicillin-resistant	S.	pneumoniae	(PRSP),	chloramphenicol	
resistance,	macrolide	 resistance,	 and	multiresistant	 strains	present	a	major	 global	
health	threat	(Appelbaum	1992;	Adam	2002;	Bogaert	et	al.	2004;	Stanek	et	al.	2011).	
The	presence	of	a	virulence-factor	target	(choline)	in	S.	pneumoniae,	and	the	rise	of	
multiresistant	 strains	 makes	 it	 an	 excellent	 candidate	 for	 endolysin	 treatment.	
Furthermore,	for	non-systemic	infections,	for	example	topical	applications	or	inhalers	
to	 reduce	nasopharyngeal	colonization,	 regulatory	 requirements	are	 less	 stringent	
thus	being	an	attractive	target	for	endolysin	proof-of-concept.		
1.4.2 Clostridium	difficile	
Clostridium	 difficile,	 which	 inhabits	 the	 gastrointestinal	 tract,	 was	 first	 isolated	 in	
1935	(Hall	and	O’Toole	1935)	and	has	had	its	whole	genome	sequenced	(Sebaihia	et	











been	 reported	 to:	 metronidazole;	 vancomycin;	 clindamycin;	 erythromycin;	
tetracycline;	moxifloxacin;	rifampicin;	and	fusidic	acid,	via	a	number	of	mechanisms	
including	ribosomal	modification,	antibiotic	efflux	and	drug	inactivation	(Huang	et	al.	





Spore-formation,	 alongside	 huge	 potential	 for	 antibiotic	 resistance,	 frequently	
results	in	a	residual	population	of	C.	difficile	surviving	in	the	human	gut	after	a	course	
of	antibiotics.	This	population	is	then	able	to	rapidly	colonise	the	gut	due	to	lack	of	














with	 a	 wide	 range	 of	 inflammatory	 diseases	 and	 implant-associated	 infections	
(Portillo	et	al.	2013).	Acne	vulgaris	is	one	of	the	most	common	global	skin	diseases,	
affecting	45	million	people	in	the	USA	and	accounting	for	approximately	20	%	of	all	
dermatologist	 appointments	 (Bhatia	 et	 al.	 2004).	 Currently	 treatments	 include	
topical	 and	 systemic	 antibiotics,	 as	 well	 as	 chemical	 treatments	 such	 as	 benzyl	
peroxide.	 However,	 growing	 antibiotic	 resistance	 and	 the	 sometimes	 severe	 side	
effects	of	chemical	therapies	call	for	a	new	solution.		
Due	to	the	prevalence	and	unsightly	nature	of	acne	vulgaris,	P.	acnes	has	been	widely	
treated	 with	 antibiotics	 for	 many	 years,	 and	 cross-resistance	 to	 clindamycin	 and	
erythromycin	was	 first	 reported	 in	1979.	Since	then,	 resistance	to	oxytetracycline,	
doxycycline,	 and	minocycline	 have	 also	 been	 reported	world-wide	 (Dessinioti	 and	


















A	 number	 of	 potential	 alternative	 antibiotics	 exists,	 each	 with	 strengths	 and	
weaknesses.	From	reviewing	 the	 literature,	 it	has	become	evident	 that	our	 future	




One	of	 the	possible	 tools	against	bacteria	 that	we	will	be	able	 to	 call	upon	 is	 the	
bacteriophage	endolysins.	The	question	remains	of	how	to	produce	them	in	a	cost-
effective	and	safe	manner.	Recombinant	expression	in	the	C.	reinhardtii	chloroplast	
provides	 a	 potential	 solution	 to	 this	 problem:	 featuring	 GRAS	 status;	 lack	 of	








1. To	 improve	 the	 level	 of	 recombinant	 endolysin	 accumulation	 in	 the	 C.	
reinhardtii	chloroplast.	













by	 Stoffels	 (2015).	 This	 convention	 is	 used	 throughout	 this	 thesis,	 and	 any	 minor	
modifications	are	noted	in	the	following	sections.	
STRAIN DESCRIPTION REFERENCE 
TN72 A recipient strain based upon the cell 
wall-less strain cw15 (mt+). Partial 
deletion of psbH gene via aadA 
cassette insertion. PSII-deficient 
mutant. Spectinomycin resistant. 
Ninlayarn 
(2012) 
TN72_SR_Control TN72 transformed with pSRSapI 





















TN72_ SR_cpl1-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1, psbH 
rescued. 
Taunt (2013) 
TN72_ SR_cpl1_CPO1-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with a 
single codon change, psbH rescued. 
This study 
TN72_ SR_cpl1_CPO2-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with a 
single codon change, psbH rescued. 
This study 
TN72_ SR_cpl1_W202A-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-202 mutated to an alanine, 
psbH rescued. 
This study 
TN72_ SR_cpl1_W209A-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-209 mutated to an alanine, 
psbH rescued. 
This study 
TN72_ SR_cpl1_W230A-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 





TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-202 and -209 mutated to 




TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-223 and -230 mutated to 





TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
tryptophan-202, -209, -223 and -230 
mutated to alanine residues, psbH 
rescued. 
This study 
TN72_ SR_cpl1_dimer-HA TN72 transformed with pSRSapI 
containing HA-tagged cpl1 with 
mutations to putatively enable 
dimerization, psbH rescued. 
This study 
		 59	
TN72_ A_cpl1_c-HA TN72 transformed with pASapI 
containing HA-tagged cpl1 encoded by 
a different DNA nucleotide sequence 




TN72 transformed with a plasmid 
containing both the HA-tagged cpl1 
under the psaA exon 1 promoter, and 
the HA-tagged cpl1_c under the atpA 
promoter, psbH rescued 
This study 
TN72_ SR_cpl1-StrepII TN72 transformed with pSRSapI 





TN72 transformed with a plasmid 
containing both the StrepII-tagged cpl1 
under the psaA exon 1 promoter, and 
the HA-tagged cpl1-c under the atpA 
promoter, psbH rescued 
This study 
TN72_SR_cd27l-HA TN72 transformed with pSRSapI 
containing HA-tagged cd27l, psbH 
rescued 
This study 
TN72_ SR_cd27l-StrepII TN72 transformed with pSRSapI 
containing StrepII-tagged cd27l, psbH 
rescued 
This study 
TN72_ WUCA2_Control TN72 transformed with pWUCA2 




TN72_ WUCA2_cph1-HA TN72 transformed with pWUCA2 
containing HA-tagged cph1, psbH 
rescued 
This study 
TN72_A_gp20-HA TN72 transformed with pASapI 
containing HA-tagged gp20, psbH 
rescued 
Taunt (2013) 
TN72_ WUCA2_gp20N-HA TN72 transformed with pWUCA2 
containing N-terminal HA-tagged 






NH4Cl 0.4 g/L 
MgSO4•7H2O 0.1 g/L 
CaCl2•2H2O 0.05 g/L 
K2HPO4 0.108 g/L 
KH2PO4 0.056 g/L 
Tris 2.42 g/L 
Trace element stock solution  1 ml/L 
Glacial acetic acid - to pH 7.0 
Bacto agar (Optional) 2 g/L 
	
2.1.1.2.2 High	salt	medium	(HSM)		
NH4Cl 0.4 g/L 
MgSO4 • 7H2O 0.1 g/L 
CaCl2 • 2H2O 0.05 g/L 
K2HPO4 0.717 g/L 
KH2PO4 0.363 g/L 
Trace element stock solution  1 ml/L 
HCl - to pH 6.9 




A	detailed	 recipe	 can	be	 found	 in	Kropat	et	al.	 (2011).	 In	brief	 seven	1000x	 stock	




STOCK SOLUTION CONCENTRATION 
IN STOCK 
COMPOSITION 
EDTA-Na2 25 mM Titrated to pH 8.0 with trace element 
grade KOH  
(NH4)6Mo7O24 28.5 µM  
Na2SeO3 0.1 mM  
Zn×EDTA 2.5 mM 2.5 mM ZnSO4 in 2.75 mM EDTA 
Mn×EDTA 6 mM 6 mM MnCl2 in 6 mM EDTA 
Fe×EDTA 20 mM 20 mM FeCl3 and 22 mM Na2CO3 in 22 
mM EDTA 
Cu×EDTA 2 mM 2 mM CuCl2 in 2 mM EDTA 
	
2.1.1.3 Culture	conditions	




































STRAIN DESCRIPTION REFERENCE 
DH5α fhuA2 Δ(argF-lacZ)U169 
phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 




Carrying pProEX HTb 
containing HA-tagged cpl1 
with mutations to induce 
dimerization 
This study 
DH5α_ProEX_gp20-HA Carrying pProEX HTb 
containing gp20 tagged on 






Bacto-tryptone 10 g/L 
Yeast Extract 5 g/L 
Sodium chloride 10 g/L 
Bacto agar (optional) 15 g/L 
	












STRAIN DESCRIPTION REFERENCE 
D39 Serotype 2, Mouse-passaged clinical 
isolate 
McDaniel et al. 
(1987) 
AL2 D39 LytA ̅ . Defined autolysin-
deficient lytA mutant of D39; Emr 





Trypticase soy broth 30 g/L 
Yeast Extract 3 g/L 
2.1.3.2.2 Columbia	blood	agar	plates	(SIGMA)	
Agar 15 g/L 
Special nutrient substrate 23 g/L 
Sodium chloride 5 g/L 


















STRAIN DESCRIPTION REFERENCE 







Heart muscle 454.0 g/L 
Peptone 10.0 g/L 
`Lab-Lemco’ powder 10.0 g/L 
Sodium chloride 5.0 g/L 
Glucose 2.0 g/L 






Brain infusion solids 12.5 g/L 
Beef heart infusion solids 5.0 g/L 
Proteose peptone 10.0 g/L 
Glucose 2.0 g/L 
Sodium chloride 5.0 g/L 
Disodium phosphate 2.5 g/L 
pH 7.4 ± 0.2 @ 25°C    
Complements:   
Vitamin K 50 mg/L 
Hemin 5 mg/L 
Resaurin 1 mg/L 
L-cysteine 0.5 g/L 
 
 
   
2.1.4.3 Culture	conditions	







STRAIN DESCRIPTION REFERENCE 
ATCC 6919 Type strain. Strain Designations: 


















PLASMID DESCRIPTION REFERENCE 
pSRSapI Based on the pUC8 backbone, 
containing the endogenous psaA 
promoter and 5’ UTR, with the rbcL 
terminator and 3’ UTR. Includes 
flanking regions around the expression 
cassette for homologous recombination 
with the chloroplast genome, and a 
functional psbH gene 
Young and 
Purton (2014) 
pSRSapI_Control pSRSapI expression vector, containing 
no gene of interest 
Young & 
Purton (2015) 
pSRSapI _cpl1-HA pSRSapI containing HA-tagged cpl1 Taunt (2013) 
pSRSapI _cpl1_CPO1-HA pSRSapI containing HA-tagged cpl1 
with a single codon change 
This study 
pSRSapI _cpl1_CPO2-HA pSRSapI containing HA-tagged cpl1 
with a single codon change 
This study 
pSRSapI _cpl1_W202A-HA pSRSapI containing HA-tagged cpl1 




pSRSapI _cpl1_W209A-HA pSRSapI containing HA-tagged cpl1 
with tryptophan-209 mutated to an 
alanine 
This study 
pSRSapI _cpl1_W230A-HA pSRSapI containing HA-tagged cpl1 





pSRSapI containing HA-tagged cpl1 
with tryptophan-202 and -209 mutated 




pSRSapI containing HA-tagged cpl1 
with tryptophan-223 and -230 mutated 





pSRSapI containing HA-tagged cpl1 
with tryptophan-202, -209, -223 and -
230 mutated to alanines  
This study 
pSRSapI _cpl1_dimer-HA pSRSapI containing HA-tagged cpl1 
with mutations to induce dimerization  
This study 
pASapI Based on the pUC8 backbone, 
containing the endogenous atpA 
promoter and 5’ UTR, with the rbcL 
terminator and 3’ UTR. Includes 
flanking regions around the expression 
cassette for homologous recombination 
with the chloroplast genome, and a 
functional psbH gene 
(Wannathong et 
al. 2016) 
pASapI_cpl1_c-HA pASapI containing HA-tagged cpl1 
with a different DNA nucleotide 




pSRSapI containing both the HA-
tagged cpl1 under the psaA exon 1 
promoter, and the HA-tagged cpl1-c 
under the atpA promoter  
This study 





pSRSapI containing both the StrepII-
tagged cpl1 under the psaA exon 1 
promoter, and the HA-tagged cpl1-c 
under the atpA promoter  
This study 
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pSRSapI _cd27l-HA pSRSapI containing HA-tagged cd27l  This study 
pSRSapI _cd27l-StrepII pSRSapI containing StrepII-tagged 
cd27l  
This study 
pWUCA2 Based upon pSRSapI, with the 
introduction of a sythetic trnWUCA gene 
Young & 
Purton (2015) 
pWUCA2_Control pWUCA2 expression vector, 
containing no GOI  
Young & 
Purton (2015) 
pWUCA2_cph1-HA pWUCA2 containing HA-tagged cph1  This study 
pWUCAC2_gp20N-HA pWUCA2 containing N-terminal HA-
tagged gp20  
This study 
pProEX HTb An expression vector confering 
Ampicilin resistance and under trc 
promoter 




pProEX_cpl1_dimer-HA-StrepII pProEX HTb containing cpl1 with 
mutations to induce dimerization. 
Tagged on the C-terminus with an HA-
tag, followed by a StrepII tag 
This study 
pProEX_gp20-HA pProEX HTb containing gp20 tagged 






NaH2PO4 59.99 g/L 
Adjust pH to 7.4 with NaOH  
2.3.1.2 Tris-HCl	
Tris                                                    121.14 g/L 





verified	with	Blastn.	 The	 sequence	 for	 an	 epitope	 tag	was	 added	before	 the	 stop	
codon,	unless	otherwise	indicated.		
EPITOPE TAG AMINO ACID 
SEQUENCE 
NUCLEOTIDE SEQUENCE 
HA tag YPYDVPDYA 
 
5' TAC CCA TAC GAT GTT CCA 
GAT TAC GCT 3' 
StrepII tag WSHPQFEK 5’ TGG TCT CAC CCA CAA TTC 
GAA AAA 3’ 












5x HF Buffer 10 µl 
Template DNA 50-100 ng 
Primers 10 pmol each 
20mM mixed dNTPs 1 µl 
Phusion polymerase 0.5 µl 





and	 the	 extension	 time	 was	 altered	 depending	 upon	 the	 length	 of	 the	 expected	
amplicon,	 according	 to	 the	 Fermentas	 Phusion	 polymerase	 instructions.	 As	 an	
example,	for	amplifying	the	entire	Cpl-1	gene	using	a	Techne	TCF3000X	thermocycler	
the	following	conditions	were	used:		
98°C  2 min  
98°C 10 s 
X 30 cycles 60°C 30 s 
72°C 30 s 
72°C 5 min  
10°C Hold  
2.3.4 PCR	DNA	Purification	
Following	 PCR,	 if	 the	 product	 was	 not	 to	 be	 loaded	 onto	 an	 agarose	 gel,	 it	 was	
“cleaned	up”	by	the	Qiagen	PCR	clean-up	kit,	as	per	the	manufacturer’s	instruction.	
The	clean-up	removed	unwanted	primers,	buffer	and	polymerase	from	the	reaction	
mixture.	 It	 was	 also	 used	 following	 restriction	 digests	 to	 remove	 small	 (<50	 bp)	
fragments	of	DNA.	
2.3.5 Agarose	gel	Electrophoresis	











































(GoI)	 from	pJet	was	 carried	out	 as	 shown	 in	 the	 table	below,	 followed	by	1	hour	
incubation	at	37	°C.	
Tango Buffer 4 µl 
LguI (SapI) 1.2 µl 
PaeI (Sph1) 1 µl 
DNA 2 µl 







Competent	 E.	 coli	 (DH5α)	 stocks,	 stored	 at	 -80°C,	 were	 thawed	 on	 ice.	 For	
transformation	using	ligation	mixes,	the	whole	10	μl	ligation	reaction	mix	was	added	
		 74	
to	 100	 μl	 of	 E.	 coli	 stock	 in	 a	 1.5	 ml	 microcentrifuge	 tube.	 For	 intact	 plasmid	
transformations,	approximately	10	ng	of	DNA	was	sufficient.	An	additional	tube	of	













which	 a	 gene	of	 interest	 can	 be	 inserted	 between	 SapI	 and	 SphI	 restriction	 sites.	
pSRSapI	can	then	rescue	photosynthetic	activity	 in	TN72	after	transformation	as	 it	
























the	 manufacturer’s	 instruction,	 while	 for	 larger	 preparations	 (<200	 μg)	 a	 Qiagen	
Midiprep	kit	was	used.		
2.3.16 E.	coli	test	digest	
Tango Buffer 1 µl 
LguI (SapI) 0.2 µl 
PaeI (SphI) 0.2 µl 
DNA sample 2 µl 
ddH2O 6.6 µl 
	




































consisted	 of	 a	 15	 %	 polyacrylamide	 resolving	 layer,	 topped	 with	 a	 3.75	 %	
polyacrylamide	stacking	layer,	as	detailed	below.	
RESOLVING GEL (FOR 2 GELS)  
Acrylamide/bisacrylamide (Sigma)40% 
stock, acrylamide:bisacrylamide = 37:1  
3.75 ml 
Resolving buffer (8x stock)0.25M Tris, 
1.92M glycine, 1% SDS, pH8.3 
1.25 ml 
10 % SDS 0.1 ml 
ddH2O 4 ml 
10 % ammonium persulphate 0.375 ml 
Tetramethylethlenediamine 3.75 μl 
	
STACKING GEL (FOR 2 GELS)  
Acrylamide/bisacrylamide (Sigma)40 % 
stock, acrylamide:bisacrylamide = 37:1  
0.47 ml 
Stacking buffer (4x stock) 0.5M Tris-HCl 
(pH 6.8) 
1.25 ml 
10 % SDS 0.05 ml 
ddH2O 3 ml 
10 % ammonium persulphate 0.25 ml 
Tetramethylethlenediamine 3.75 μl 
	
RESERVOIR BUFFER (10X STOCK)  
Tris     0.25 M 
Glycine 1.92 M 
SDS 1 % 








The	C.	 reinhardtii	 culture	was	 resuspended	 as	 for	 the	 SDS-PAGE	preparation.	 The	
freeze-thaw	method	was	then	used	to	mechanically	break	the	cells	(3	x	freezing	in	
liquid	nitrogen,	thawing	at	35	°C).	Then	the	samples	were	centrifuged	(16,200	g,	2	




The	SDS	gel	was	 incubated	 in	Coomassie	Brilliant	Blue	R	 solution	 for	1	hour,	with	
gentle	 agitation,	 followed	 by	washing	 in	 destaining	 solution	 overnight.	 Gels	were	
photographed	using	the	LiCor	Odyssey®	CLx	imaging	system.	
Coomassie	Blue	Solution:	
Coomassie Brilllant Blue R250 2.5 g/L 
Acetic acid 100 ml/L 
Methanol 450 ml/L 
ddH2O 450 ml/L 
	
Destaining	Solution:	
Acetic acid 100 ml/L 
Methanol 450 ml/L 
















ANTIBODY SOURCE DILUTION 
Primary antibodies   
Anti-HA (polyclonal, 
rabbit) 
Sigma Aldrich, #H6908 1:2,000 
Anti-rbcL (polyconal, 
rabbit) 
Gift from J. Gray, 





Abcam, #ab76949 1:2,000 
Secondary antibodies   




















assay	 was	 performed	 in	 a	 96	 well	 plate.	 This	 was	 performed	 according	 to	 the	
manufacturer’s	 instructions	 (Sigma	Aldrich).	Bovine	serum	albumin	 (BSA)	dilutions	


















bead	 abrasion	 (1	 g	 of	 0.4	 mm	 diameter	 glass	 beads	 was	 added	 per	 10	 ml	 of	
concentrated	cells,	followed	by	vigorous	shaking	at	4°C	for	10	minutes).	Subsequently	
the	 broken	 cell	 suspension	 was	 centrifuged	 at	 21,000	 g	 for	 10	 minutes	 and	 the	
supernatant	collected.	The	supernatant	is	referred	to	as	crude	protein	extract.	




Ultracentrifuged	 crude	 protein	 extracts	 were	 stirred	 on	 ice	 and	 powdered	







pump	 and	 eluted	 using	 2.5	 mM	 desthiobiotin	 in	 binding	 buffer,	 as	 per	 the	
manufacturer’s	instructions.	
2.6 E.	coli	protein	preparation	






































method	 was	 used,	 adapted	 from	 Hyvonen	 (2002).	 Sonication	 was	 used	 to	 lyse	
induced	E.	coli	cells	resuspended	 in	10mM	Tris-HCl	buffer	 (pH	8.0)	as	described	 in	
2.6.4,	and	the	resulting	supernatant	was	used	for	this	analysis.	To	create	an	oxidising	













with	 endolysin	 samples	 and	 incubated	 at	 37	 °C	 for	 1	 hour.	 The	 mixture	 was	
subsequently	diluted	in	ten	10-fold	dilution	steps.	20μl	of	dilution	numbers	6-10	were	







of	 bacterial	 suspension	 and	 50	 μl	 of	 filter	 sterilized	 cell	 lysate	 or	 buffer	 were	
incubated	at	37	°C	for	0,	30,	60,	90,	120	or	150	minutes.	10	μl	samples	were	taken	
after	 the	 incubation	 time	 from	 each	 combination	 and	 spotted	 in	 triplicate	 onto	











Unless	 otherwise	 stated,	 20	μl	 of	 antimicrobial	 sample,	with	 varying	 total	 soluble	
protein	quantities	were	added	to	280	μl	of	suspension	of	the	target	bacterium.	As	a	
positive	 lysis	 control	 for	 S.	 pneumoniae	 turbidity	 reduction	 assays,	 20	 μl	 of	


































toll	 of	 1.6	 million	 people,	 mainly	 young	 children	 and	 the	 elderly	 in	 developing	
countries	(WHO	2007).	
In	1987	the	39	kDa	protein	of	Cp1	was	characterised	as	a	muramidase	and	named	


































reinhardtii,	we	 speculate	 that	 purifying	 recombinant	 Cpl-1	 from	 the	C.	 reinhardtii	
chloroplast	may	not	be	required	to	be	as	rigorous,	and	therefore	be	cheaper.		
3.1.2 Factors	to	consider	in	protein	accumulation	
The	 relatively	 low	 levels	 of	 recombinant	 protein	 accumulation	 achieved	 in	 the	C.	
reinhardtii	chloroplast,	when	compared	to	existing	platforms	such	as	E.	coli,	offer	an	
area	 for	 improvement.	 This	 chapter	 discusses	 two	 techniques	 investigated	 to	
improve	accumulation	of	the	Cpl-1	protein	in	the	C.	reinhardtii	chloroplast.		
When	protein	accumulation	is	considered,	one	must	break	the	issue	down	into	two	






levels	 of	 transcription,	 does	 not	 appear	 to	 improve	 the	 final	 levels	 of	 protein	
accumulation	(Coragliotti	et	al.	2011).	Given	the	polyploid	nature	of	the	C.	reinhardtii	
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promoters	were	inserted	into	the	chloroplast	in	order	to	potentially	overcome	the	
process	 of	 Control	 by	 Epistasy	 of	 Synthesis	 (Choquet	 et	 al.	 1998).	 Secondly,	




A	 comparable	 endolysin,	 Pal,	 produced	 by	 Stoffels	 (2015)	 achieved	 slightly	 lower	
levels	of	accumulation:	5	mg	L-1	or	13	mg	g-1	dry	weight.	These	offer	a	bench	mark	
upon	which	we	should	aim	to	improve.	However,	in	this	thesis	dry	cell	weight	was	
not	 considered,	 as	 generally	we	were	 interested	 in	 relative	 improvements,	 rather	
than	actual	yields	of	protein.	However,	moving	forward	a	clear	understanding	of	dry	










We	 hypothesize	 in	 this	 chapter	 that	 the	 CES	 process	 is	 limiting	 the	 level	 of	




















are	 frequently	 used	 codons,	 but	 ACC:CUG	 and	 CUG:ACC	 are	 translated	 at	 very	
different	rates.		
Previous	 work	 by	 Taunt	 (2013)	 recognised	 a	 similar,	 non-random	 distribution	 of	
codon	pairs	 in	the	C.	reinhardtii	chloroplast	plastome.	One	pair	 in	particular	stood	
out	as	appearing	extremely	non-random,	the	phenylalanine:arginine	pair,	UUU:CGU.	
Under	 a	 random	 codon	 distribution,	 one	 would	 expect	 to	 observe	 this	 pair	
approximately	 28	 times	 in	 the	 chloroplast	 plastome,	 but	 in	 fact	 it	 never	 occurs.	










4. To	produce	 two	 transgenic	 lines	of	C.	 reinhardtii	with	different	 codon	pair	
optimization	strategies.	





The	 first	 hurdle	 to	 overcome	 when	 attempting	 to	 improve	 protein	 accumulation	








When	 comparing	 two	 or	more	 algal	 cultures,	 one	must	 be	 sure	 to	 inoculate	 the	
culture	with	the	same	number	of	cells.	This	immediately	introduces	an	opportunity	
for	error,	which	here	we	aim	to	quantify.	There	are	essentially	two	practised	methods	





400ml	 TAP	medium	were	 inoculated	with	 equal	 starter	 volumes	 from	 a	 single	C.	
reinhardtii	 starter	 culture.	 These	 were	 incubated	 and	 measured	 in	 the	 Algem	
photobioreactor	for	96	hours.	After	this,	the	three	flasks	(labelled:	a,	b	and	c)	were	
		 92	




















































Three	 different	 samples	 were	 then	 taken	 from	 the	 same	 flasks	 and	 their	 OD740	
measured	in	the	same	manner:	
	











1 2 3 St.	Dev. %	error
Culture
a 252 322 267 36.86 4.38%
b 223 281 220 34.39 4.75%
c 248 275 220 27.50 3.70%
Av. 32.91 4.28%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.541 0.532 0.540 0.0040 0.25%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 0.0025 0.17%
Av. 0.0052 0.35%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.532 0.569 0.538 0.0162 0.99%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 0.0024 0.17%
Av. 0.0093 0.60%
Count Calculations
1 2 3 St.	Dev. %	error
Culture
a 252 322 267 36.86 4.38%
b 223 281 220 34.39 4.75%
c 248 275 220 27.50 3.70%
Av. 32.91 4. 8
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.541 0.532 0.540 0.0040 0.25%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 .0025 17
Av. .0052 35
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.532 0.569 0.538 0.0162 0.99%
b 0.509 0.499 0.522 0.0094 0.62%



























1 2 3 St.	Dev. %	error
Culture
a 252 322 267 36.86 4.38%
b 223 281 220 34.39 4.75%
c 248 275 220 27.50 3.70%
Av. 32.91 4.28%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.541 0.532 0.540 0.0040 0.25%
b 0.479 0.499 0.480 0.0092 0.63%
c 0.499 0.503 0.505 0.0025 0.17%
Av. 0.0052 0.35%
OD750 Calculations
1 2 3 St.	dev. %	error
Culture
a 0.532 0.569 0.538 0.0162 0.99%
b 0.479 0.499 0.480 0.0092 0.63%




















technical	 repeats	 onto	 an	 SDS	 gel	 and	 probed	 with	 anti-HA	 primary	 antibodies,	
followed	by	Goat	anti-Rabbit	IgG	(H+L)	Secondary	Antibody	IRDye®	800CW	(referred	













error	 in	 Figure	 3.4,	 the	 endogenous	 protein	 RbcL	 (which	 is	 the	 large	 subunit	 of	
Ribulose-1,5-bisphosphate	carboxylase/oxygenase	(RuBisCo),	the	product	of	the	rbcL	
gene),	 was	 probed	 with	 an	 anti-RbcL	 primary	 antibody	 on	 the	 same	 blot	 and	
Culture	A Culture	B Culture	C
Replicate
1 22800 59300 34800
2 50700 51900 27400
3 39400 35800 25500 Average


































There	 appears	 to	 be	 little	 correlation	 between	 the	 RbcL	 and	HA	 detection	 levels,	
although	similar	levels	of	error	are	observed	between	replicates.	This	could	be	due	
to	a	number	of	factors.	Possibly	the	blotting	efficiency	varied	across	the	membrane,	
so	 proteins	 were	 unevenly	 blotted	 from	 the	 SDS	 gel	 onto	 the	 nitrocellulose	
membrane.	It	could	also	be	due	to	uneven	antibody	decoration	of	the	blot,	suggesting	
a	 longer	blotting	 time	 is	necessary.	 Finally,	 the	quantification	 technique	using	 the	
Culture	A Culture	B Culture	C
HA RbcL HA RbcL HA RbcL
Rep.
1 22800 20600 59300 22500 34800 15600
2 50700 19700 51900 24000 27400 4930
3 39400 23000 35800 18000 25500 17100 HA	Av. RbcL Av.

































































with	 Cpl-1	 detection	 at	 higher	 concentrations,	 but	 more	 variable	 at	 lower	








































10	x 6 x 3	x
(kDa)	
		 101	
correlation	 to	 anti-HA	 tagged	 protein	 detection.	 This	 is	 most	 likely	 due	 to	 the	











the	 same	 standard	 in	 all	 western	 blot	 analyses,	 one	 can	 normalize	 between	
membranes,	if	for	example	they	have	been	blotted	for	slightly	different	amounts	of	






proteins	 in	C.	 reinhardtii	 cell	 extracts	 have	 been	 compared.	 However,	 the	 results	
obtained	 in	 this	 manner	 have	 been	 unreliable	 due	 to	 several	 factors	 including	
degradation	 of	 the	 protein	 standards,	 the	 unknown	 efficiency	 of	 blotting	 to	















was	 sequenced	 to	 confirm	 the	 correct	 insertion	 and	 used	 to	 transform	 DH5α	
competent	E.	coli	cells.	
The	resulting	E.	coli	strain	was	named	DH5α_ProEX_cpl1_dimer-HA-StrepII,	and	 its	











The	 IPTG-induced	 DH5α_ProEX_cpl1_dimer-HA-StrepII	 cells	 were	 lysed	 using	



















was	 then	 used	 for	 protein	 enrichment	 via	 a	 commercially	 available	 StrepTactin	
column	(Thermo	Fisher	Scientific).	The	purification	fractions	are	shown	in	Figure	3.9.		
	










































































































































































a	 similar	 size	 is	 detected	 in	 TN72_SR_Control,	 whole	 cell	 extracts	 of	 each	 were	
prepared	and	separated	by	SDS-PAGE.	A	blot	of	the	gel	was	then	probed	with	an	anti-




























system	 for	 targeted	 insertion	 into	 the	 chloroplast,	 we	 have	 only	 one	 plastome	
insertion	site;	namely,	the	neutral	site	between	psbH	and	trnE2.	The	two	expression	
cassettes,	containing	the	same	gene	of	interest,	will,	therefore,	need	to	be	adjacent	
to	 one	 another	 in	 the	 transformation	 plasmid,	 and	 be	 integrated	 by	 a	 single	
transformation	event	into	the	plastome	by	homologous	recombination.		
The	gene	of	 interest	 in	 this	 instance	 is	cpl1	which	 is	~1	kb	 in	 length.	Homologous	

























However,	 two	 identical	 copies	 of	 cpl1	 in	 close	 proximity	 to	 one	 another	 are	









to	 leave	a	viable	expression	cassette	 in	 the	 chloroplast	plastome,	 thus	 still	 produce	Cpl-1	
protein.	
However,	 as	 illustrated	 in	 Figure	 3.17,	 by	 arranging	 the	 expression	 cassettes	 in	
antiparallel	directions,	recombination	events	will	merely	result	in	a	switching	of	the	
promoter	regions	and	no	loss	of	DNA	will	occur.	









are	 highly	 similar.	 Furthermore,	 Coragliotti	 et	 al.	 (2011)	 report	 no	 detectable	
difference	in	expression	as	a	result	of	transgene	orientation.	In	fact,	the	C.	reinhardtii	
chloroplast	contains	two	large	inverted	repeat	regions	which	allow	similar	“flip-flop”	





repeated	 cpl1	 genes,	 one	 gene	 was	 differently	 codon	 optimized	 to	 reduce	 the	
sequence	 similarity.	 The	different	 version	of	cpl1	was	named	cpl1_c,	with	 the	 “c”	
standing	for	codon	changed.	
3.3.2.2.1.1 Cpl-1_c	gene	design	
The	 original	 genetic	 sequence	 for	 cpl1	 as	 used	 by	 Taunt	 (2013),	 and	 present	 in	
TN72_SR_cpl1-HA,	was	uploaded	to	Codon	Usage	Optimizer	Beta	0.92	(Kong	2013)	
software	 and	 codons	were	manually	 edited	 to	 ones	 of	 similar	 “scores”	 for	 the	C.	
reinhardtii	 chloroplast.	 In	 total	 148	nucleotides	were	 changed	out	of	 1050	 (14	%)	
without	affecting	the	overall	score	for	codon	usage.	SapI	and	SphI	restriction	sites	
were	included	for	cloning.		
5’psaA 1 cpl1-HA 3’rbcL5’atpA3’rbcL cpl1-HA

















psbH.R.	 Figure	 3.19	 shows	 the	 resulting	 PCR	 products	 separated	 by	 gel	
electrophoresis.	TN72	was	used	as	a	negative	control.	As	a	final	step,	the	sequence	























































































restriction	site	at	 the	3’	end	of	 the	A_cpl1-c-HA	cassette.	As	MluI	and	BssHII	 form	
compatible	 restriction	 sites,	 the	 cpl1-c	 containing	 expression	 cassette	was	 ligated	
into	the	open	vector,	producing	one	conserved	MluI	site.	The	resulting	plasmid	was	
called	 pSRSapI_cpl1-HA_A_cpl1_c-HA.	 It	 is	 believed	 that	 the	 alternative	
arrangement,	i.e.	opening	the	pASapI_cpl1-c-HA	plasmid	and	inserting	the	SR_cpl1-
HA	 cassette,	would	 have	 also	 been	 possible,	 but	when	 both	were	 attempted	 the	
cloning	succeeded	with	the	former	first	and	therefore	this	route	was	continued.	
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Figure	 3.22	 TN72	 recipient	 strain	 transformed	 with	 the	 pSRSapI_cpl1-HA_A_cpl1_c-HA	
plasmid,	thus	rescuing	psbH	activity.	Carrying	cpl1-HA	under	the	psaA	5’	UTR,	and	cpl1_c-HA	
under	the	atpA	5’	UTR	in	the	chloroplast.	
The	 resulting	 transformants	 were	 confirmed	 to	 be	 homoplasmic	 as	 described	 in	
2.3.17	and	represented	in	Figure	3.23.	Finally,	correct	insertion	into	the	plastome	was	






5’psaA 1 cpl1-HA 3’rbcL5’atpAcpl1_c-HA3’rbcL
		 116	
	
Figure	 3.23	 (A)	 Schematic	 describing	 the	 expected	 band	 when	 testing	 homoplasmic	
transformants.	The	combination	which	produces	 the	negative	band	can	be	seen	 in	Figure	
3.19.	 It	 is	the	absence	of	the	negative,	350	bp,	band	that	 indicates	homoplasmicity	 i.e.	no	






the	 same	gene	does	 indeed	 improve	overall	 protein	accumulation	 levels	 in	 the	C.	
reinhardtii	chloroplast,	western	blot	analysis	was	performed.	Whole	cell	extracts	of	
TN72_SR_cpl1-HA	 and	 TN72_SR_cpl1-HA_A_cpl1_c-HA	 were	 prepared,	 and	 five	
































nitrocellulose	 membrane	 as	 described	 in	 2.4.5,	 the	 membrane	 was	 stained	 with	
REVERT™	Whole	Protein	Stain	which	confirmed	similar	quantities	of	cell	preparation	
were	 loaded	 onto	 the	 gel	 (Appendix	 A)	 and	was	 used	 to	 normalize	 small	 loading	






C.	 reinhardtii	 lines.	 Cpl-1	 detection	 was	 normalised	 using	 the	 signal	 from	 REVERT	 Total	
Protein	Stain.		
A	two	sample	t-test	was	carried	out	to	compare	the	levels	of	protein	accumulation	in	














































The	 full	 results	 can	 be	 seen	 in	 Figure	 3.25,	 but	 in	 brief,	 there	 was	 a	 significant	









































SapI	 and	 SphI	 restriction	 enzymes	were	used	 to	 clone	 the	 gene	 in-frame	 into	 the	















The	 resulting	 transformants	 were	 confirmed	 for	 homoplasmicity	 as	 described	 in	




were	 prepared	 and	 separated,	 in	 duplicate,	 by	 SDS-PAGE.	 After	 blotting	 to	
nitrocellulose	membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 one	membrane	was	
probed	with	an	anti-HA	primary	antibody,	while	the	second	membrane	was	probed	
with	anti-StrepII	primary	antibody.	Both	membranes	were	then	incubated	by	IRDye®	
secondary	 antibody	 and	 fluorescence	was	observed	using	 the	 LiCor	Odyssey®	CLx	
system.	The	resulting	images	are	shown	in	Figure	3.27.	
	
Figure	 3.27	 Two	 duplicate	membranes	 were	 probed	with	 anti-HA	 or	 anti-StrepII	 primary	
antibodies	and	Cpl-1	accumulation	was	detected	in	the	expected	cell	lines	i.e.	Cpl-1-HA	was	
detected	with	the	anti-HA	antibody	and	not	with	the	anti-StrepII	antibody	and	vice	versa.	The	































Figure	3.28	TN72	 recipient	 strain	 successfully	 transformed	 to	 carry	cpl1-StrepII	 under	 the	
psaA	 5’	 UTR,	 and	 cpl1_c-HA	 under	 the	 atpA	 5’	 UTR	 in	 the	 chloroplast,	 and	 with	 psbH	
functionality	restored.	









membranes	 as	 described	 in	 2.4.5	 and	 REVERT™	 Total	 Protein	 stain	 was	 used	 to	
normalise	 loading	 error	 (Appendix	 C).	 One	 membrane	 was	 probed	 with	 anti-HA	
primary	antibody,	while	the	second	membrane	was	probed	with	anti-StrepII	primary	






















accumulation.	Other	 strains	 are	 represented	 relative	 to	 this.	 Protein	 accumulation	 of	 the	
StrepII	tagged	Cpl-1	appears	to	be	considerably	lower	than	that	of	the	HA	tagged	protein.	












































































































































plausible	 that	 a	 little	 of	 both	 scenarios	may	 be	 occurring,	 given	 that	 the	 protein	
standard	is	tagged	with	an	HA	tag	at	the	C-terminal	end,	followed	by	the	StrepII	tag	
beyond	that.	Anti-HA	antibodies	could	therefore	be	slightly	hindered	by	the	presence	
of	 the	 StrepII	 tag,	 while	 anti-StrepII	 antibodies	may	 find	 the	 epitope	 to	 be	more	
accessible	due	to	its	slightly	increased	protuberance	from	the	Cpl-1	protein.		









The	 second	 aspect	 of	 this	 chapter	 looks	 at	 using	 codon	 pair	 optimization	 as	 a	
technique	for	improving	recombinant	protein	accumulation	levels	in	the	C.	reinhardtii	
chloroplast.	Codon	optimization	is	a	well-known	approach	to	improve	recombinant	
protein	 yields,	 and	 has	 been	 shown	 to	 be	 particularly	 important	 for	 transgene	
expression	 in	 the	C.	 reinhardtii	 chloroplast	 –	 Franklin	 et	 al.	 (2002b)	 increased	gfp	
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expression	 by	 80-fold	 in	 a	 codon	 optimized	 version	 compared	 to	 a	 unoptimized	
version.	 The	 codon	 frequency	 chart	 for	 the	C.	 reinhardtii	 chloroplast	 is	 shown	 in	
Appendix	D.	Taunt	(2013)	 investigated	the	role	that	codon	pairs	play	and	whether	
these	 too	 could	be	optimized	 to	 improve	expression.	 The	 study	 identified	 several	
codon	pairs	which	had	high	predicted	occurrence	but	were	rarely	or	never	observed	
in	 the	 C.	 reinhardtii	 chloroplast	 plastome.	 These	 pairs	 were	 terms	 Unexpectedly	
Unseen	 Zero	 Scoring	 Codon	 Pairs	 (uuZSCP).	 Two	 such	 uuZSCP	 stood	 out	 as	 being	
particularly	significant,	a	Phenylalanine:Arginine	pair,	and	an	Aspartic	Acid:Leucine	
























Phe:Arg UUU 0.67 CGU 0.73 0.49 28.29 0







examination	 of	 the	 data	 and	 checking	 the	 chloroplast	 genome	 (GenBank:	
BK000554.2)	 for	 tRNA	 genes	 using	 tRNAscan-SE	 (http://lowelab.ucsc.edu/cgi-
bin/tRNAscan-SE),	a	couple	of	inaccuracies	in	the	tRNA	data	were	noticed.	Firstly,	the	
trnE	gene	is	counted	three	times,	when	in	fact	there	appear	to	be	only	two	copies	




tRNA	genes	and	 seems	 to	be	 inconsistent.	 For	example,	 there	are	 trnR	 and	 trnR2	
genes,	which	identify	tRNAs	with	different	anticodons,	but	no	trnR1	exists.	A	table	of	
all	the	tRNA	genes	in	the	C.	reinhardtii	chloroplast	has	been	compiled	in	Figure	3.33.	


























Phe	 Arg	 CPAI	 Present	in…	
UUU	 CGU	 0	 cpl1	
UUU	 CGC	 0	 	
UUU	 CGA	 0	 	
UUU	 CGG	 0	 	
UUU	 AGA	 0	 	
UUU	 AGG	 0.0625	 cpov2	
UUC	 CGU	 1	 cpov1	
UUC	 CGC	 0	 	
UUC	 CGA	 0.0625	 	
UUC	 CGG	 0	 	
UUC	 AGA	 0.0625	 	











Figure	3.33	A	 list	of	tRNA	genes	 identified	by	Maul	et	al.	 (2002).	The	yellow	rows	indicate	
duplicate	tRNA	genes,	i.e.	they	have	the	same	anticodon.	Green	rows	indicate	tRNA	genes	
with	different	anti-codons,	but	coding	for	the	same	amino	acid.		





2 trnC GCA UGC Cys





5 trnF GAA UUC Phe
6 trnG1 UCC GGA Gly
7 trnG2 GCC GGC Gly





10 trnK UUU AAA Lys
11 trnL1 UAG CUA Leu
12 trnL2 UAA UUA Leu
13 trnM1 CAU AUG fMet
14 trnM2 CAU AUG Met
15 trnM3 LAU AUA Ile
16 trnN GUU AAC Asn
17 trnP UGG CCA Pro
18 trnQ UUG CAA Gln
19 trnR1 ACG CGU Arg
20 trnR2 UCU AGA Arg
21 trnS1 UGA UCA Ser
22 trnS2 GCU AGC Ser
23 trnT UGU ACA Thr
24 trnV UAC GUA Val
25 trnW CCA UGG Trp




Several	 naming	 changes	 have	 been	 made	 in	 Figure	 3.33	 to	 the	 original	 names	
published	in	Maul	et	al.	(2002).	The	new	names	fall	in	line	with	the	annotations	made	
to	 the	 chloroplast	 genome	 available	 at	 NCBI	
(https://www.ncbi.nlm.nih.gov/nuccore/BK000554).	The	names	mean	that	identical,	
duplicate	genes	 (trnA,	 trnI	and	 trnE)	have	 the	same	anticodon,	while	genes	which	
encode	 similarly	 charged	 tRNAs,	but	with	differing	anticodons,	 are	numbered	e.g.	
trnL1	and	trnL2.	The	only	change	made	from	the	NCBI	naming	is	to	name	both	trnE	
genes	the	same,	as	they	are	identical	duplicates.	It	should	also	be	noted	that	some	
discrepancy	exists	between	 the	defined	gene	 length	on	NCBI	and	 the	 tRNA	genes	






Figure	 3.34	 The	C.	 reinhardtii	 chloroplast	 chromosome.	 tRNA	 genes	 are	 identified	 on	 the	
outer	ring	in	black	and	labelled	with	a	single	letter.	e.g.	V,	which	indicates	trnV.	Two	tRNA	
genes	 (trnA	 and	 trnI)	 are	 located	 in	 the	 Inverted	 Repeat	 (IR)	 regions	 of	 the	 plastome,	
indicated	in	thick	black,	thus	explaining	their	duplication.	The	second	copy	of	trnL	(2	o’clock)	
should	be	black	to	indicate	tRNA,	as	should	trnI	and	trnA	on	the	right-hand	IR.	Reproduced	






the	 phenomenon	 known	 as	 tRNA	 wobble	 (Alkatib	 et	 al.	 2012).	 CPOCv1	 would	
therefore	act	as	a	control	 for	 this	 investigation,	as	 the	 theory	being	 tested	 is	 that	
tRNAs	interact	in	the	A	and	the	P	site	of	the	ribosome	in	a	manner	that	can	influence	



































































of	 the	 plasmid	 as	 described	 in	 2.3.18.	 The	 resulting	 plasmids	 were	 called	
pSRapI_CPOCv1-HA	and	pSRapI_CPOCv2-HA.	
3.3.3.1.3 C.	reinhardtii	transformation	
Two	 TN72	 transformations	 were	 performed,	 using	 pSRSapI_CPOCv1-HA	 and	
pSRSapI_CPOCv2-HA	 plasmids.	 Transformed	 C.	 reinhardtii	 lines	 were	 checked	 for	
homoplasmicity	by	PCR	and	finally	confirmed	by	sequencing.		
3.3.3.2 Western	 blot	 quantification	 of	 TN72_SR_CPOCv1-HA	 and	
TN72_SR_CPOCv2-HA	
It	is	hypothesised	that	the	codon	changes	made	above	will	result	in	different	levels	
of	protein	accumulation	between	 the	 two	 transformant	 lines.	To	 test	 this,	 four	C.	
reinhardtii	cultures,	TN72_SR_cpl1-HA,	TN72_SR_CPOCv1-HA,	TN72_SR_CPOCv2-HA	

















The	 quantified	 and	 normalised	 data	 is	 displayed	 in	 Figure	 3.38,	 alongside	 optical	




A	 one-way	 ANOVA	 test	 was	 carried	 out	 on	 the	 recombinant	 protein	 yields	 of	
TN72_SR_cpl1-HA,	 TN72_SR_CPOCv1-HA	 and	 TN72_SR_CPOCv2-HA	 in	 order	 to	




difference	 beyond	 this	 point.	On	 the	 other	 hand,	 the	 second	 performance	 of	 the	
experiment	was	run	for	longer	and	likewise,	suggests	that	protein	accumulation	of	
TN72_SR_CPOCv2	is	significantly	higher	the	45	and	56-hour	time	points.	However,	
CPOCv1	 and	 CPOCv2	 then	 continue	 to	 rise,	 while	 the	 protein	 accumulation	 in	
TN72_SR_cpl1-HA	rises	at	a	much	lower	rate,	being	significantly	lower	than	the	codon	









































































SR_cpl1-HA	Protein SR_CPOCv1-HA	Protein SR_CPOCv2-HA	Protein SR_Control	Protein




















































SR_cpl1-HA	Protein SR_CPOCv1-HA	Protein SR_CPOCv2-HA	Protein SR_Control	Protein













times	 and	 slightly	 different	 dilutions	 of	 milk	 and	 antibody.	 Assuming	 that	 these	
variables	 are	 the	 same	 within	 membranes,	 but	 can	 vary	 from	 membrane	 to	










This	 is	 an	 interesting	 observation,	 as	 according	 to	 the	 theory	 of	 codon	 pair	
optimisation,	CPOCv1	accumulation	should	be	no	different	to	the	unchanged	Cpl-1,	
as	 the	 tRNAs	 serving	 the	 mRNA	 are	 identical.	 However,	 particularly	 in	 the	 later	
growth	 stages	 in	 Figure	 3.39,	 there	 is	 a	 consistently	 and	 significantly	 higher	
accumulation	of	CPOCv1	and	CPOCv2.		
Given	 the	 evidence	 from	 section	 3.3.1,	 in	 which	 data	was	 collected	 on	 the	 error	
introduced	at	various	points	of	measuring	protein	accumulation,	these	differences	
seem	 too	 large	 to	 be	 artefacts	 of	 variability	 in	 western	 blotting	 and	 cell	 density	
measuring	 techniques.	 Therefore,	 alternative	 explanations	 for	 this	 result	must	 be	
sought.	
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the	beneficial	effects	of	 the	 former	are	negated	by	 the	detrimental	effects	of	 the	
latter.	 There	 is	 no	 similar	 effect	made	 by	 CPOv1,	 as	 all	 Phenylalanine	 codons	 are	
served	by	a	single	tRNA.	
Arg	 Arg	 CAI	 Present	in…	
CGU	 CGU	 1	 cpl1	&	cpov1	
CGC	 CGU	 0	 	
CGA	 CGU	 0	 	
CGG	 CGU	 0	 	
AGG	 CGU	 0	 	
AGA	 CGU	 0	 cpov2	
Figure	3.40	Data	taken	from	the	“hand-pick”	database	of	Codon	Usage	Optimizer	Beta	0.92	







Additionally,	 the	 unexpectedly	 unseen	 nature	 of	 UUU:CGU	 could	 be	 just	 a	
coincidence.	Although	this	seemed	unlikely,	given	the	convincing	statistical	analysis	





confer	 no	 difference	 in	 translational	 efficiency	 or	 codon	 selection.	 It	 could	 be	
therefore	that	some	neutral	mechanism	has	resulted	in	this	bias,	not	selection,	for	
example,	 preferential	mutation	bias	 during	DNA	 replication	or	 repair	 (Lucks	 et	 al.	
2008).	Another	alternative	is	that	the	single	base	change	in	the	cpl1	transgene	has	
created	 an	 unexpected	 local	 area	 of	 secondary	 structure	 within	 the	 mRNA,	 thus	
altering	 the	 translational	efficiency	 (Gaspar	et	al.	2013).	This	kind	of	 interaction	 is	




between	“identical”	C.	 reinhardtii	chloroplast	 transformants	 (Mayfield	and	Schultz	
2004;	 Surzycki	 et	 al.	 2009;	 Michelet	 et	 al.	 2011).	 The	 differences	 can	 be	 quite	
remarkable:	 Surzycki	 et	 al.	 (2009)	 reported	 that	 recombinant	 protein	 expression	
levels	of	VP28,	a	White	Spot	Syndrome	virus	protein,	varied	between	transformants	
from	0.88	%	to	20.9	%	TCP.	When	only	a	low	number	of	transformants	are	generated,	
as	 is	 frequently	 the	case	with	the	glass	bead	method	regularly	used	 in	 the	Purton	
group,	 a	 significant	 difference	 in	 transgene	 expression	 could	 be	 incorrectly	
apportioned	 to	 a	 factor	 which	 really	 has	 little	 effect.	 The	 reason	 put	 forward	 by	
Surzycki	 et	 al.	 (2009)	 for	 this	 observation	 is	 transformation-associated	 genotypic	
modifications,	termed	the	“transformosome”.	The	paper	postulates	that	during	the	
process	 of	 genetic	 transformation,	 fragments	 of	 the	 transformation	 plasmid	 are	
unknowingly	 inserted	 into	 the	plastome	or	 nuclear	 genome,	 thus	 altering	nuclear	
genes	 that	 regulate	 chloroplast	 gene	 expression,	 protease	 expression,	 or	 sites	 of	
regulatory	 gene	 action	 in	 the	 chloroplast.	 Evidence	 is	 presented	 that	 the	 level	 of	
steady	state	transgene	mRNA	is	unaffected,	giving	further	weight	to	the	belief	that	
gene	regulation	occurs	primarily	at	the	translation	level	in	C.	reinhardtii.	
C.	 reinhardtii	 is	 extremely	 good	 at	 resource	management,	 and	 as	 such	 is	 able	 to	






the	 value	 for	 protein	 accumulation	 is	 relative	 (i.e.	 it	 has	 been	 normalised	 for	 the	
optical	density	of	the	culture),	Figures	3.38	and	3.39	both	show	increasing	levels	of	
protein	 accumulation	 as	 the	 culture	 progresses	 into	 stationary	 phase	 and	 then	 it	








This	 chapter	 has	 investigated	 two	 putative	 methods	 of	 improving	 recombinant	
protein	 expression	 in	 the	 C.	 reinhardtii	 chloroplast:	 the	 introduction	 of	 multiple	
expression	 cassettes;	 and	 the	 application	 of	 codon	 pair	 optimisation.	 The	 former	
appears	to	be	a	method	to	robustly	improve	protein	accumulation,	while	the	latter	
method	 remains	 unclear	 as	 the	 complex	 and	 incremental	 nature	 of	 the	 change	
appears	to	be	masked	by	other	factors	in	play.	Interestingly	the	concern	addressed	
at	the	start	of	the	chapter,	namely	how	to	accurately	compare	protein	accumulation	




multiple	 expression	 cassettes	 produce	 a	 recombinant	 protein	 yield	 approximately	










its	 accumulation	 under	 a	 single	 5’	 UTR,	 thus	making	 it	 a	 good	 candidate	 for	 this	









site	 to	 be	 used	 and	 targeted	 for	 transformation,	 requiring	 the	 use	 of	 a	 second	
selectable	marker,	 enabling	 sequential	 transformations.	 Two	 options	 exist	 in	 this	
case,	 either	 the	 addition	 of	 a	 positive	 selectable	 marker,	 such	 as	 aadA	 and	
maintaining	 the	 algae	 on	 spectinomycin	 containing	 media,	 or	 the	 addition	 of	 a	
negative	selectable	marker,	such	as	codA,	to	the	recipient	line	which	is	then	replaced	
in	the	second	transformation	event	(Young	and	Purton	2014).	The	latter	would	result	
in	 the	 formation	 of	 a	 marker-less	 mutant	 which	 is	 desirable	 for	 further	
transformations	but	requires	more	time	to	make	the	constructs.	As	an	initial	test	of	
how	 far	 the	multiple-cassette	 theory	 can	 be	 taken,	 it	 is	 suggested	 that	 using	 an	
antibiotic	 resistance	marker	 is	more	straightforward.	Furthermore,	 the	practice	of	
using	codon	manipulation	to	minimise	the	potential	for	DNA	excision,	as	performed	
in	3.3.2.2.1.1,	may	enable	more	cassettes	to	be	inserted	into	the	same	site.	However,	
given	 that	 codon	 optimisation	 has	 been	 shown	 to	 be	 very	 influential	 in	 protein	



















achieved	 in	 the	 literature.	 Alternatively,	 an	 ELISA	 assay	 could	 be	 performed	 but	






transformants,	 also	 known	 as	 “clonal	 variation”,	 has	 the	 potential	 to	 mask	 or	
exaggerate	 investigations	 into	 other	methods	 of	 improving	 protein	 accumulation.	
Until	this	issue	has	been	addressed,	“fine-tuning”	techniques	will	remain	difficult	to	
assay	and	are	unlikely	to	be	as	effective	as	simply	screening	many	transformants	and	
selecting	 the	 best,	 as	 many	 protein	 production	 companies	 working	 with	 Pichia	
pastoris	currently	do	(Aw	et	al.	2017).	
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The	 most	 useful	 tool	 to	 aid	 investigation	 into	 this	 phenomenon	 would	 be	 the	
development	 of	 a	 sensitive	 and	 robust	 reporter	 gene	 for	 C.	 reinhardtii.	 Reporter	
genes	 such	 as	GFP	 have	 been	used	 for	 this	 purpose	 in	many	 other	 organisms,	 as	
fluorescence	 is	 graded	 and	 easily	 measured	 in	 vivo,	 enabling	 rapid	 quantitative	






Schultz	 2004).	 Surzycki	 et	 al.	 (2009)	 demonstrated	 that	 co-introduced	 selectable	
marker	genes	are	expressed	in	a	manner	proportional	to	the	GOI.	Therefore,	the	co-
introduction	of	luciferase	with	a	GOI	should	enable	its	fluorescence	to	be	used	as	a	

























Development	 of	 the	 above	 will	 enable	 more	 precise	 testing	 of	 other	 strategies	
including	 codon	 and	 codon	 pair	 optimization.	 The	 above	 also	 depends	 upon	 the	
development	of	a	more	efficient	system	of	transforming	C.	reinhardtii	chloroplast,	as	
many	 transformants	need	 to	be	 rapidly	produced	 for	 this	method	 to	be	effective.	






















which	 codons	 to	 use	 in	 a	 transgene.	 It	 seems	 intuitive	 that	 just	 using	 the	 most	






When	one	 is	 trying	to	express	proteins	 for	commercial	uses,	generally	 the	highest	
possible	level	of	protein	accumulation	is	desired,	something	that	the	host	cell	rarely	
attempts	to	do	in	natura.	On	the	other	hand,	bacteriophage,	which	infect	host	cells	





inter-species	 codon	 map,	 by	 which	 one	 can	 map	 a	 rare	 codon	 in	 Streptococcus	
pneumoniae	to	a	rare	codon	in	C.	reinhardtii	for	example,	thus	conserving	the	pattern	
of	“fast”	and	“slow”	codons	that	has	been	optimised	over	millennia.		
Overall,	 this	 study	 demonstrates	 that	 there	 is	 huge	 potential	 to	 improve	 protein	
accumulation	 yields	 in	 the	 C.	 reinhardtii	 chloroplast,	 and	 the	 technique	 of	 using	
multiple	expression	cassette	insertions	appears	to	be	a	robust	method	of	improving	
protein	yields.	However,	other	methods	of	improving	protein	accumulation	such	as	
codon	 pair	 optimisation	 firstly	 require	 improvements	 in	 understanding	 of	 clonal	







endolysin,	 Cpl-1,	 in	 its	 ability	 to	 lyse	S.	 pneumoniae	 cells.	 Several	 strategies	were	
tested	with	this	aim	in	mind,	namely:	manipulating	the	cell	wall	binding	site	of	Cpl-1;	
attempting	to	form	pre-dimerised	Cpl-1	endolysins	in	the	C.	reinhardtii	chloroplast;	








bacterium,	 thus	 allowing	 the	 release	 of	 phage	 progeny	 into	 the	 environment	 in	
search	 of	 another	 bacterial	 host.	 The	 endolysin,	 therefore,	 should	 lyse	 only	 the	
current	 host	 cell,	 and	 not	 neighbouring	 bacterial	 cells,	 which	 could	 be	 potential	
future	hosts	 for	 the	progeny.	One	characteristic	of	endolysins	 is	 that	 they	tend	to	
bind	strongly,	often	in	the	pico-	to	nanomolar	range	(Loessner	et	al.	2002),	to	their	
substrate	 -	 it	 has	 been	 postulated	 that	 this	 is	 a	 tethering	 mechanism	 to	 reduce	
unintentional	damage	to	nearby	bacteria	(Chapot-Chartier	2014).		
This	feature,	while	beneficial	to	bacteriophage,	often	reduces	the	activity	level	of	the	
endolysin	 as	 an	 enzyme	 as	 it	 restricts	 its	 lytic	 activity	 to	 a	 localised	 area	 of	 the	
peptidoglycan	 cell	 wall	 (Nelson	 et	 al.	 2001).	 For	 some	 endolysins,	 such	 as	 Cpl-1,	









we	 propose	 that	 if	 binding	 could	 be	 weakened,	 activity	 may	 be	 improved.	 With	
weaker	binding,	the	endolysin	may	be	able	to	release	after	lysis	and	repeat	its	lytic	
actions	elsewhere,	thus	making	the	endolysin	more	suited	to	a	therapeutic	role.	This	








From	 a	 protein	 engineering	 perspective,	 Gram-positive-targeting	 endolysins	 are	





















Cpl-1	 is	 known	 to	be	 cleared	 from	 the	blood	plasma	of	mice	 in	 approximately	20	
minutes	(Witzenrath	et	al.	2009),	presenting	a	possible	issue	for	systemic	use.	Resch	
et	al.	(2011)	hypothesised	that	a	“pre-dimerised”	Cpl-1	homodimer	would	be	a	more	


















side-chain	of	 the	aromatic	 residue	 involved	 in	dimerisation.	Reproduced	 from	Buey	et	 al.	
(2007).	
Figure	4.2	does	not	show	the	acidic	linker	joining	the	two	domains	of	each	monomer	












creating	a	hole	 in	 the	cytoplasmic	membrane	of	 the	bacterium	(Young	1992).	The	
timing	of	 this	 event	 is	 critically	 important	 to	 the	 success	 of	 the	bacteriophage	by	
controlling	 the	 length	 of	 the	 cycle,	 and	 thus	 the	 holin	 gene	 is	 under	 enormous	
selective	pressure	(Wang	et	al.	2000).	It	is	perhaps	due	to	this	selective	pressure	that	
holins	 are	 such	 a	 diverse	 functional	 group,	 comprising	 seven	 superfamilies	
encompassing	52	recognised	families	with	no	clear	conserved	sequence	motif	(Reddy	
and	 Saier	 2013).	 However,	 all	 holins	 have	 certain	 characteristics	 including	 the	
possession	of	at	least	one	transmembrane	α-helical	sequence	and	a	highly	charged	
hydrophilic	C-terminal	domain	(Gu	et	al.	2014).	

















Figure	4.3.	However,	 this	binding	 is	PMF	 (proton	motive	 force)-dependent:	as	 the	




















the	 peptidoglycan	 layer,	 nor	 how	 capsules	 and	 slime-layers	 affect	 holin	 access.	
Further	investigation	of	holin	structure	and	its	potential	as	a	novel	antibacterial	has	










4. To	 compare	 the	 activity	 of	 the	 CBS	 mutant	 Cpl-1	 proteins	 against	 S.	
pneumoniae.	
















an	endolysin,	Kd	≈	3.6	mM	 (Monterroso	et	al.	 2008),	however	 the	 requirement	of	
bacteriophages	to	tether	their	endolysins	to	only	the	host’s	cell	wall	suggests	that	it	







to	 be	 of	 importance	 for	 hydrogen	 bonding	 during	 endolysin	 binding	 and	 two	
tryptophan	residues	and	one	tyrosine	were	identified	in	each	binding	site	to	fit	these	




investigation,	 the	 two	 tryptophan	 residues	 in	 each	 binding	 site	were	 selected	 for	
mutation.	
																																																						










are	 approximately	 one	 Angstrom	 in	 length	 is	 accounted	 for,	 the	 hydrogen	 bonds	
formed	 in	 these	 interactions	 cover	 approximately	 3-4	 Angstroms.	 According	 to	
Jeffrey	 (1997),	 hydrogen	 bonds	 over	 this	 distance	 range	 from	 “moderate,	mostly	
electrostatic”	to	“weak,	electrostatic”.	
	
Figure	 4.4	 The	 two	 active	 choline	 binding	 sites	 in	 the	 CBD	 of	 Cpl-1.	 Distances	 are	 in	
Angstroms.	It	should	be	noted	that	the	distances	are	between	the	nitrogen	(blue)	and	oxygen	
(red)	atoms,	so	are	not	a	direct	representation	of	a	hydrogen	bond	length	as	the	hydrogen	
must	 be	 accounted	 for	 too	 in	 each	 case.	 However,	 these	 remain	 “moderate/weak	 and	
electrostatic”	hydrogen	bonds.	













and	 therefore	 seven	C.	 reinhardtii	 cell	 lines	 expressing	 cpl1	with	 either	 individual	
tryptophan	mutations	or	combinations	of	tryptophan	mutations	were	generated.		
	



























mutants.	 The	 naming	 of	 each	 construct	 indicates	 the	mutation	 location	 and	 nature,	 e.g.	
cpl1_W202A-HA	is	the	cpl1	gene	with	tryptophan-202	mutated	to	an	alanine	residue,	and	
tagged	with	an	HA	tag.	Multiple	mutations	are	separated	by	an	underscore.	
A	 pair	 of	 primers	 was	 designed	 for	 each	mutation,	 as	 displayed	 below,	 with	 the	
mutation	site	in	lowercase,	and	start	and	stop	codons	underlined.	cpl1.F	and	cpl1.R	
are	the	primers	at	the	start	and	end	of	the	gene.	







Trp202 Trp209 Trp223 Trp230
TGG TGG TGG TGG
GCT TGG TGG TGG
TGG GCT TGG TGG
TGG TGG GCT TGG
TGG TGG TGG GCT
GCT GCT TGG TGG
TGG TGG GCT GCT



















Figure	 4.8	 Site	 directed	mutagenesis	was	 performed	 as	 above	 to	mutate	 the	 tryptophan	
encoding	codon,	TGG,	to	the	alanine	encoding	one,	GCT.	Primers	are	shown	in	blue	and	PCR	
conditions	are	described	in	2.3.7.	






















The	C.	 reinhardtii	 recipient	 line	TN72	was	 transformed	by	 the	glass	bead	method,	
using	 the	 pSRSapI_cpl1	 plasmids	 (2.3.13).	 The	 resulting	 transformed	 lines	 are	
represented	in	Figure	4.9.	Photosystem	II	functionality	is	restored	by	psbH	and	the	
resulting	 transformants	 were	 capable	 of	 growing	 phototrophically	 on	 minimal	
medium.	Each	of	the	six	transformed	lines	was	shown	to	reach	a	homoplasmic	state	
by	 PCR	 as	 described	 in	 2.3.17.	 As	 a	 final	 step,	 the	 integrity	 of	 the	 cassette	 was	
confirmed	by	DNA	sequencing	of	the	PCR-amplified	plastome	region,	as	in	2.3.18.	
	
Figure	 4.9	 The	 resulting	 C.	 reinhardtii	 lines	 express	 the	 mutated	 cpl1	 gene	 under	 the	




PAGE	 and	 blotted	 to	 nitrocellulose	 membrane	 for	 western	 blot	 analysis.	 The	
membrane	 was	 probed	 with	 anti-HA	 primary	 antibodies	 followed	 by	 IRDye®	























































































































































































































































As	 discussed	 at	 length	 in	 3.3.2.2.4.3,	 the	 reason	 for	 the	 difference	 in	 protein	





Cpl-1	 activity.	 To	 measure	 this	 activity	 several	 approaches	 were	 taken,	 namely:	
turbidity	 reduction	 assays	 and	 colony	 forming	 unit	 assays,	 using	 both	 crude	 cell	





used	 therapeutically,	 particularly	 for	 topical	 applications,	 thus	 removing	 the	
expensive	requirement	to	purify	the	final	protein.		
It	was	 therefore	 investigated	whether	crude	extracts	of	 the	six	Cpl-1	CBS	mutants	
described	 in	 this	 section	 display	 different	 levels	 of	 lytic	 activity	 towards	 S.	
pneumoniae,	when	compared	to	the	activity	of	the	un-mutated	Cpl-1	protein.		
Crude	extracts	were	prepared	as	described	in	2.4.1.	In	brief,	the	six	C.	reinhardtii	cell	
lines	 were	 grown	 simultaneously	 and	 their	 OD740	 measured	 after	 72	 hours.	 The	
cultures	were	centrifuged	and	the	pellet	resuspended	in	20	mM	NaPi	buffer	to	give	
suspensions	of	equivalent	cell	density	measured	at	OD740.	The	cells	were	 lysed	by	
freeze-thaw	 and	 ultracentrifuged	 to	 remove	 the	 cell	 debris.	 The	 supernatant	was	
stored	 at	 4	 °C	 and	 this	was	 considered	 the	 “crude	 extract”.	 Fresh	 S.	 pneumoniae	








































From	 Figure	 4.12,	 it	 appears	 that	 the	 un-modified	 TN72_SR_cpl1-HA	 is	 the	most	
active	 endolysin,	 while	 all	 the	 mutated	 endolysins	 showed	 activity	 intermediate	















to	 partially	 purify	 and	 concentrate	 the	 Cpl-1	 CBS	mutants,	 providing	 an	 enriched	
crude	 extract.	 The	 enriched	 extracts	 were	 separated	 by	 SDS-PAGE,	 blotted	 to	


















































































































































































































































bacterial	 suspension	 containing	 endolysin	 were	 performed	 after	 one	 hour	 of	
incubation	at	37	°C,	and	three	10	μl	drops	of	each	dilution	were	spotted	onto	blood	
agar	plates.	The	mean	count	across	the	three	spots	was	calculated.	The	data	from	









































equal	 quantities	of	 endolysin	have	been	achieved,	 this	 has	probably	 resulted	 in	 a	
different	 level	of	 total	protein,	because	ammonium	sulphate	precipitation	enables	
the	 enrichment	 of	 all	 proteins	 within	 a	 range	 of	 solubility,	 which	 undoubtedly	
includes	many	other	proteins.	In	order	to	include	similar	quantities	of	the	HA-tagged	
Cpl-1	CBS	mutant	 protein,	 differing	 volumes	of	 the	 ammonium	 sulphate	 enriched	
extract	were	used,	 thus	altering	 the	osmotic	pressure	on	the	bacterial	cells	 in	 the	
suspension.	In	this	case	too,	it	is	worth	noting	that	the	20	mM	NaPi	buffer	is	causing	

















flow-through,	which	 suggests	 that	 there	 are	 background	 proteins	 fluorescing	 and	
disguising	 the	 HA-tagged	 proteins	 in	 these	 fractions.	 However,	 these	 background	


















































extract	 enriched	 using	 the	 HA	 tag.	 Only	 mutants	 which	 have	 visible	 enriched	 bands	 are	
shown.	The	bands	were	quantified	used	the	LiCor	Odyssey®	CLx	system	and	the	results	are	
shown	 in	 the	 bar	 chart.	 The	 percentage	 of	 recovered	 protein	 ranged	 from	 33%	 for	 the	
unmodified	 Cpl-1	 to	 only	 6%	 recovery	 for	 the	 Cpl1-W202A_W209A_W223A_W230A-HA	
protein.		
Only	 three	 of	 the	 Cpl-1	 CBS	 mutants	 achieved	 sufficient	 levels	 of	 protein	
accumulation	to	enable	a	colony	forming	unit	assay	to	be	performed.	
The	 colony	 forming	 unit	 assay	was	 performed	 using	 the	 same	 batch	 of	 frozen	 S.	
pneumoniae	 cells	 as	 in	 Figure	 4.14.	 The	C.	 reinhardtii	 crude	 extracts	 and	 the	HA-
purified	elutions	were	diluted	such	that	they	contained	equal	concentrations	of	HA-
tagged	protein	before	being	used.	The	method	can	be	found	in	2.7.1.1.	The	number	











purified	 TN72_SR_Control	 appears	 to	 achieve	 the	 second	 highest	 level	 of	
antibacterial	activity.	The	buffer	control	sits	nearly	in	the	middle	of	the	crude	extract	
and	 purified	 extract	 activities,	 which	 lends	 weight	 to	 the	 argument	 that	 osmotic	
pressure	is	reducing	cell	lysis	in	the	crude	extracts.	The	un-mutated	Cpl-1	protein	has	
the	greatest	antibacterial	effect,	while	the	Cpl-1	CBS	mutants	are	no	more	effective	






The	HA	epitope	has	been	widely	used	 in	 the	Purton	 group,	 as	well	 as	 other	 algal	
research	 groups.	 The	 original	 expression	 of	 cpl1	 in	 C.	 reinhardtii	 encoded	 an	 HA	
epitope	 tag	 on	 its	 C-terminus	 (Taunt	 2013),	 and	 this	 was	 continued	 into	 this	
investigation.	However,	while	convenient	for	western	blot	detection,	using	the	HA-
tag	 for	 protein	 purification	 is	 expensive	 compared	 to	 some	 other	 epitopes,	 as	 it	
involves	affinity	purification	using	an	anti-HA	monoclonal	antibody.	The	StrepII	tag	
was	chosen	as	an	alternative	as	 it	has	been	used	 in	the	algal	 field	to	purify	native	
chloroplast	 proteins	 from	 C.	 reinhardtii	 (Derrien	 et	 al.	 2012;	 Derrien	 2013).	
Furthermore,	 as	 the	 system	 is	 based	 on	 the	 affinity	 of	 biotin	 and	 streptavidin,	
purification	columns	are	relatively	cheap.	3.3.2.2.3	describes	the	production	of	the	C.	















Odyssey®	 CLx	 system	 enabled	 the	 StrepII-tagged	 protein	 recovery	 to	 be	 estimated	 as	 a	
percentage	of	the	ultracentrifuged	(UC)	extract	passed	through	the	column.		
Approximately	 one-third	 of	 the	 total	 protein	 remains	 in	 the	 supernatant	 on	
ultracentrifugation,	but	virtually	100%	of	this	was	recovered	using	the	HiTrap	StrepII	
column.	 Further	 optimisation	 of	 ultracentrifugation	 speeds	 and	 durations	 could	















Figure	 4.19	 Colony	 forming	 unit	 assay	 of	 S.	 pneumoniae	 cells	 treated	 with	 Cpl1-StrepII	
enriched	extracts.	“Control”	refers	to	a	purified	extract	from	TN72_SR_Control.	The	number	
of	 colony	 forming	 units	 was	 counted	 by	 eye	 and	 when	 an	 uncountable	 lawn	 of	
indistinguishable	 colonies	 was	 present,	 this	 was	 counted	 as	 100.	 The	 count	 was	 then	
averaged	across	the	three	spots.	Three	dilutions	of	the	enriched	extract	were	tested	(100	%,	
75	 %	 and	 25	 %),	 and	 the	 percentage	 indicates	 the	 initial	 concentration,	 not	 the	 final	
concentration	(i.e.	prior	to	mixing	with	the	bacterial	suspension).	
		 175	
The	 colony	 forming	 unit	 assay	 in	 Figure	 4.19	 indicates	 a	 measurable	 difference	
between	the	three	Cpl-1	dilutions,	and	they	are	clearly	more	active	than	the	extract	
from	TN72_SR_Control	at	the	two	higher	concentrations.	These	data	suggest	that	this	











this	 case	 would	 allow	 easy	 comparison	 of	 different	 mutants.	 The	 best	 of	 these	
mutants,	if	indeed	cell	wall	binding	site	mutagenesis	can	improve	endolysin	activity,	
could	then	be	expressed	in	C.	reinhardtii	for	the	final	therapeutic	drug	production.	In	









Resch	 et	 al.	 (2011)	 showed	 that	 Cpl-1	 can	 be	 modified	 to	 “pre-dimerise”,	 thus	
decreasing	plasma	clearance	and	improving	its	clinical	potential.		
Cpl-1	 is	 stable	 as	 a	monomer,	 but	 Cpl-1	 dimerisation	 occurs	 naturally	 on	 choline	
binding	 (Buey	 et	 al.	 2007).	 We	 expect	 that	 the	 addition	 of	 a	 disulphide	 bridge	
between	 two	 Cpl-1	 monomers	 will	 reduce	 the	 rate	 of	 degradation	 in	 storage	 by	
limiting	both	protease	access	and	the	denaturing	of	the	protein,	as	well	as	achieving	
the	decreased	plasma	clearance	reported	by	Resch	et	al.	(2011).	The	aim	is	also	to	




















the	 stability	 of	 monomeric	 Cpl-1	 when	 stored	 under	 lab	 conditions.	 If	 Cpl-1	
dimerisation	can	be	achieved,	then	this	stability	may	be	improved,	thus	enabling	the	
addition	 of	 less	 protease	 inhibitor	 which	 would	 reduce	 costs	 and	 simplify	 the	
therapeutic	regulatory	procedure.		
4.3.2.2 Production	of	a	C.	reinhardtii	line	expressing	cpl-1	dimer		
The	 pre-dimerised	 Cpl-1	 protein	 produced	 by	 Resch	 et	 al.	 (2011)	 was	 achieved	
through	 site-directed	mutagenesis,	 and	 their	 experiments	 are	 briefly	 summarised	
here:	 site-directed	 mutagenesis	 firstly	 changed	 a	 cysteine	 residue	 near	 the	 N-
terminus	(C45)	to	a	serine	(see	Figure	4.21).	This	first	step	removed	the	possibility	of	
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interactions	 with	 this	 solvent-accessible	 cysteine.	 Then	 an	 aspartic	 acid	 residue	
(D324),	 in	a	position	13	amino	acids	away	from	the	C-terminus,	was	mutated	to	a	















mutated	 to	 a	 serine	 to	 prevent	 unwanted	 interactions,	 as	 this	 cysteine	 is	 believed	 to	 be	





then	 transformed	with	 the	 resultant	 plasmid	 and	 DNA	 sequencing	 confirmed	 the	
correct	insertion	and	that	the	intended	mutations	had	been	successfully	introduced.	
4.3.2.2.3 C.	reinhardtii	transformation	
The	 TN72	 recipient	 line	 was	 transformed	 with	 the	 pSRSapI_cpl1_dimer-HA	





Whole	 cell	 extracts	 of	 TN72_SR_cpl1-HA	 and	 TN72_SR_Control	 (as	 controls)	 and	
TN72_SR_cpl1_dimer-HA	were	prepared,	both	with	and	without	β-mercaptoethanol	
(BME),	 and	 separated	 by	 SDS-PAGE.	 The	 BME	 reduces	 disulphide	 bonds	 so	 was	
included	to	test	if	the	dimerised	Cpl-1	could	be	detected	when	BME	was	absent	but	
not	 when	 present	 –	 this	 would	 confirm	 disulphide	 presence.	 After	 blotting	 to	
nitrocellulose	 membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 the	 membrane	 was	
probed	 with	 anti-HA	 primary	 antibody,	 then	 incubated	 with	 IRDye®	 secondary	
antibody.	 Fluorescence	 was	 observed	 using	 the	 LiCor	 Odyssey®	 CLx	 system.	 The	
resulting	analysis	is	shown	in	Figure	4.22.	
	
Figure	4.22	Western	blot	 analysis	of	 TN72_SR_cpl1_dimer-HA.	 The	 loading	mixture	either	
contained	β-mercaptoethanol	or	did	not,	indicated	by	+/-	BME.	The	predicted	band	location	
for	Cpl-1_dimer	is	indicated	but	no	bands	were	observed.		
No	 spontaneously	 forming	 Cpl-1	 dimers	were	 observed	 in	 the	whole	 cell	 extract.	








The	 addition	 of	 the	 small	molecule	 selenocystamine	 to	 the	 growth	medium	of	C.	
reinhardtii	 was	 reported	 to	 catalyse	 disulphide	 bond	 formation	 in	 recombinant	
proteins	(Ferreira-Camargo	et	al.	2015).		
Selenocystamine	was	added	to	C.	 reinhardtii	 cultures	 to	a	 final	concentration	of	2	
μM,	the	optimal	concentration	observed	by	Ferreira-Camargo	et	al.	 (2015).	Whole	





Figure	 4.23	 Western	 blot	 analysis	 of	 whole	 cell	 C.	 reinhardtii	 extracts,	 grown	 with	

































As	 shown	 in	 Figure	 3.8,	 the	 E.	 coli	 line	 DH5α_pProEX_cpl1_dimer-HA-StrepII	 was	
shown	 to	 express	 Cpl-1	 to	 a	 high	 level,	 and	 the	 application	 of	HiTrap	 StrepTactin	





pair	of	 cysteines.	 In	Gram-negative	prokaryotes,	 such	as	E.	 coli,	 this	occurs	 in	 the	
periplasmic	 space,	 where	 enzymes	 catalyse	 the	 reaction.	 Recombinant	 proteins	
therefore	require	an	N-terminal	signal	peptide	to	target	them	to	the	periplasm	for	
disulphide	bond	 formation,	which	was	not	 included	on	our	cpl1_dimer	 transgene.	







and	can	 therefore	be	 formed	 in	vitro	 (Berkmen	2012).	Glutathione	 is	a	commonly	
used	 reagent	 in	 its	 reduced	 (GSH)	 and	 oxidised	 (GSSH)	 form	 to	 produce	 a	 redox	
environment	beneficial	to	disulphide	bond	formation.	The	protocol	is	described	fully	
in	2.6.5,	adapted	from	Hidaka	et	al.	(1998)	and	Hyvonen	(2002).	
A	 crude	 cell	 lysate	of	E.	 coli	 cells	 induced	 to	express	cpl1_dimer	was	obtained	by	
sonication,	and	ultracentrifugation	removed	the	insoluble	fraction.	An	existing	Cpl-
1_StrepII	enriched	extract	from	C.	reinhardtii	was	used	as	a	control	(from	4.3.1.3.6).	



















Cpl-1	 dimer	 formation	 in	 subsequent	 lanes,	 however	 this	 seems	 unlikely,	 as	 one	
would	expect	to	be	able	to	see	two	bands	even	if	they	were	located	close	together	









































and	 Purton	 2015).	 Given	 the	 ability	 of	 holins	 to	 form	 holes	 in	 the	 cytoplasmic	
membrane	of	E.	coli,	and	thus	inhibit	cell	growth	(Catalão	et	al.	2011),	the	use	of	the	
pSRSapI	plasmid	to	clone	these	in	E.	coli	is	unlikely	to	be	possible.	




of	 interest	 is	 modified	 to	 contain	 several	 UGA	 codons	 in	 the	 place	 of	 UGG	
(Tryptophan)	–	these	are	read	as	“Stop”	codons	by	the	E.	coli	translational	machinery,	





Figure	4.26	The	pWUCA2	 transformation	vector	 is	based	upon	pSRSapI	and	has	 the	same	
cloning	 sites	 for	 the	 GOI	 and	 the	 same	 flanking	 regions	 for	 homologous	 recombination.	
However,	 an	 additional	 synthetic	 gene,	 trnWUCA,	 has	 been	 inserted	 upstream	 of	 the	 GOI	
expression	cassette.	
This	 strategy	 enables	 the	 cloning	 in	E.	 coli	 of	 genes	 under	 functional/constitutive	
promoters,	which	would	otherwise	produce	proteins	that	are	toxic	or	detrimental	to	
		 187	






overcome	 by	 the	 use	 of	 induction	 systems,	 but	 allows	 only	 10	 –	 15	 minutes	 of	
accumulation	before	the	metabolic	activity	fails	(Smith	et	al.	1998).	Furthermore,	the	
nature	of	the	protein	means	that	it	must	be	purified	from	the	bacterial	membrane	to	












































Figure	4.29	Western	blot	analysis	 indicates	 that	a	~15	kDa	protein	 is	detected	by	anti-HA	
antibodies	 in	 the	 TN72_WUCA2_cph1-HA	extract,	 and	not	 in	 the	negative	 control.	 This	 is	
likely	to	be	Cph-1	protein.		
Cph-1	 appeared	 to	 be	 present	 in	 TN72_WUCA2_cph1-HA	 whole	 cell	 extract.	
However,	it	was	noted	that	the	transformed	C.	reinhardtii	lines	did	not	appear	to	be	
as	 healthy	 as	 other	 lines,	 in	 that	 they	 took	 a	 longer	 time	 to	 reach	 a	 bright	 green	
culture,	taking	approximately	six	days	rather	than	the	usual	three	or	four.	This	was	
merely	 an	 observation,	 and	 no	 data	 was	 collected	 at	 the	 time	 to	 objectively	
investigate	a	change	in	growth	rate.		
4.3.3.1.5 Investigation	into	holin	localisation	
Given	the	non-specific	 insertion	of	holins	 into	bacterial	cell	membranes,	 it	 is	 likely	
that	 the	 holin	 would	 insert	 into	 chloroplast	 membranes	 when	 produced	 as	 a	






and	 cytoplasmic	 fraction	 (supernatant).	 However,	 when	 the	 two	 fractions	 were	







at	a	normal	 rate	and	 it	had	recovered	 from	 its	earlier	unhealthy	appearance.	This	
observation	and	the	lack	of	detectable	Cph-1	accumulation	suggested	that	the	gene	
had	been	silenced	 in	some	way,	either	 through	point	mutations	or	 recombination	
events	between	similar	sequences.	
4.3.3.1.6 Investigating	cph1	silencing	
Figure	 4.28	 demonstrates	 that	 the	 three	 TN72_WUCA2_cph1-HA	 lines	 were	
homoplasmic,	meaning	that	all	of	the	~70	chloroplast	genome	copies	contained	the	
desired	expression	cassette.	This	was	achieved	by	several	rounds	of	selection	upon	
minimal	 medium,	 thus	 selecting	 for	 photosynthetically-competent	 cells	 and	
promoting	 the	 presence	 of	 the	 transformed	 plastome	 copies.	 However,	 once	
homoplasmicity	had	been	achieved	and	confirmed,	cells	were	grown	mixotrophically	
upon	 acetate	 and	 under	 light	 which	 promotes	 faster	 growth.	 Had	 the	 cell	 been	
heteroplasmic	 at	 this	 stage	 and	 the	 GOI	 was	 sufficiently	 toxic,	 it	 is	 possible	 that	














2014).	 Furthermore,	each	of	 these	 repeated	 sequences	 is	 relatively	 small:	 trnW	 is	







confirmation	 of	 homoplasmicity.	 Sequencing	 confirmed	 the	 presence	 of	 both	 the	
holin	 and	 trnWUCA	 genes,	 with	 no	mutations.	 The	 psbH.R	 primer	 binds	 inside	 the	
downstream	flanking	region	of	the	transformation	plasmid,	and	123a	binds	upstream	









of	d	&	e	here	suggests	 that	 the	cassette	 is	no	 longer	present	 in	 the	 intended	neutral	 site	







does	 note	 that	 recombination	 has	 been	 observed	with	 relatively	 small	 repeats	 in	
Chlamydomonas,	 for	 example,	 216	 bp	 direct	 repeats	 in	 the	 chlL	gene	 are	 able	 to	
		 193	















It	 is	 noted	 in	 4.3.1.1.1	 and	 illustrated	 in	 Figure	 4.4	 that	 there	 are	 three	 residues	
believed	 to	 be	 of	 key	 importance	 in	 each	 choline	 binding	 site,	 two	 tryptophan	
residues	and	a	tyrosine	residue.	Hermoso	et	al.	(2003)	also	suggest	that	a	lysine	is	
involved	 in	 capping	 the	 site	 and	 stabilising	 the	 phosphate	 group	 of	 phosphoryl-
choline.	This	investigation	only	considered	the	two	tryptophan	residues	of	each	site,	
simply	 due	 to	 time	 constraints	 and	 the	 fact	 that	 they	 appear	 to	 be	 closer	 to	 the	
choline	 residue.	 It	 appears	 that	 mutating	 the	 tryptophan	 residues	 did	 indeed	
negatively	affect	 choline	binding,	but	 that	 this	 resulted	 in	 reduced	 lytic	activity.	 It	
would,	therefore,	be	interesting	to	consider	the	tyrosine	and	lysine	in	each	binding	















insert	 the	 gene	 into	 pJet,	 a	 vector	 from	 a	 commercially	 available	 PCR	 cloning	 kit	
(ThermoFischer),	enabling	blunt	end	cloning	and	transformation	of	E.	coli.	No	E.	coli	





An	 interesting	 and	 related	 point	 of	 discussion	 is	why	 the	 inactive	 choline	 binding	
repeats	(p4-p6)	remain	so	highly	conserved.	As	these	repeats	appear	to	be	sterically	
unable	 to	 bind	 choline,	 it	 would	 be	 reasonable	 to	 assume	 that	 there	 was	 little	







purported	 inactivity,	 an	 alternative	 protein	 engineering	 focus	 could	 be	 taken.	 For	
example,	the	flexible	acidic	linker	that	joins	the	cell	wall	binding	domain	and	catalytic	
domain	would	be	an	interesting	site	for	improvement.	If	it	is	indeed	the	case	that	the	











AGAGAS	 (6),	AGAGAGAGAS	 (10),	AGAGAGAGAGAGAS	 (14),	 and	AGAGAGAGAGAGAGAGAS	
(18).	Reproduced	from	Briers	et	al.	(2014).	
The	acidic	 linker	 for	Cpl-1	 comprises	 residues	189-199,	with	amino	acid	 sequence	
DDEEDDKPKTA.	While	not	directly	analogous	to	the	linker	investigated	by	Briers	et	al.	
(2014),	 it	would	be	 interesting	 to	attempt	 to	extend	 the	Cpl-1	 linker	 to	 see	 if	any	
improvement	 in	 activity	 can	 be	 achieved.	 However,	 it	 is	 unlikely	 that	 much	
improvement	to	activity	can	be	gleaned	by	extending	the	acidic	linker,	as	this	would	
have	probably	been	highly	selected	for	throughout	evolution.	This	is	in	contrast	to	






method	 was	 not	 used	 in	 this	 investigation,	 as	 choline	 binding	 was	 the	 object	 of	







have	 benefitted	 from	 testing	 a	 larger	 number	 of	 mutants	 more	 quickly.	 For	 this	
reason,	the	choice	of	C.	reinhardtii	as	a	platform	limited	these	initial	investigations,	
as	 transformations	 take	 more	 time,	 recombinant	 protein	 yields	 are	 lower,	 and	








(2011)	 demonstrated	 that	 pre-dimerised	 Cpl-1	 had	 a	 10-fold	 reduction	 in	 plasma	
clearance	and	a	two-fold	increase	in	activity.	Secondly,	the	C.	reinhardtii	chloroplast	
is	known	to	control	redox	reactions	and	is	capable	of	catalysing	disulphide	bonds	in	




















stable	 than	 the	monomer.	 An	 investigation	 can	 also	 be	 carried	 out	 into	whether	










accumulation	 of	 the	 holin	 Cph-1	 in	 the	 C.	 reinhardtii	 chloroplast	 but	 found	 that	
accumulation	quickly	ceased.	
The	‘silencing’	of	Cph-1	is	worthy	of	investigation,	as	chloroplast	transformations	are	
not	 usually	 susceptible	 to	 gene	 silencing,	 although	 it	 is	 common	 in	 nuclear	






as	discussed	previously,	even	 if	 this	was	 the	case	 it	 seems	unlikely	 that	 the	strain	




genome.	 However,	 the	 same	 investigation	 failed	 to	 confirm,	 or	 refute,	 that	 the	
cassette	was	 located	 in	 the	 targeted	 location,	namely	between	the	 trnE	and	psbH	
genes	in	the	chloroplast.	A	primer	located	beyond	the	psbH	gene	is	required	so	that	
the	 entire	 region	 can	 be	 amplified	 to	 confirm	 that	 the	 cassette	 is	 not	 present	 or	
otherwise	-	this	would	be	very	straightforward.		
We	 know	 that	 over	 the	 millennia	 since	 the	 first	 photosynthetic	 prokaryote	 was	
engulfed	into	a	eukaryote	to	become	a	chloroplast,	the	vast	majority	of	the	genetic	
information	 from	the	chloroplast	genome	has	been	eliminated	or	migrated	 to	 the	
nucleus,	leaving	only	genes	essential	for	photosynthesis	in	the	chloroplast	(Howe	and	
Purton	2007).	It	is	possible	that	the	highly	undesirable	cph1-containing	cassette	has	
been	 translocated	 to	 the	 nucleus	 under	 a	 similar	 mechanism,	 and	 once	 there,	
silencing	mechanisms	are	prolific.	The	potential	mechanism	for	such	a	DNA	relocation	
is	 not	 understood,	 but	 such	 a	 mechanism	 is	 known	 to	 exist	 (Cullis	 et	 al.	 2009).	





Regardless	 of	 the	 mechanism	 used	 by	 the	 C.	 reinhardtii	 cells	 to	 prevent	 Cph-1	
accumulation,	 it	 clearly	 is	 not	 tolerated	 by	 the	 cell.	 It	 is	 likely	 that	 the	 holin	was	
























Cpl-1	 accumulated	 to	 a	 relatively	 high	 level,	 approximately	 1%	 of	 total	 soluble	





However,	while	 several	 fusion	 proteins	were	 created	 to	 test	 this	 theory,	 no	 clear	
conclusions	 could	 be	 drawn.	 Additionally,	 work	 by	 Dr	 Laura	 Stoffels,	 also	 of	 the	
Purton	group,	achieved	expression	and	activity	of	the	S.	pneumoniae	endolysin	Pal,	








Current	 work	 in	 the	 Purton	 Group	 by	 Juliana	 de	 Costa	 Ramos	 (unpublished)	 is	
focussed	 upon	 producing	 endolysins	 targeting	 Gram-negative	 bacteria.	 Two	 such	
endolysins	 (LysAB2	 and	 LoGT-023)	 have	 been	 successfully	 expressed	 in	 the	 C.	
reinhardtii	 chloroplast,	 and	 although	 the	 ‘target	 bacteria’	 for	 both	 endolysins	 is	
Acinetobacter	baumannii,	Gram-negative	endolysins	 tend	 to	be	much	 less	 specific	
than	 those	 targeting	 Gram-positive	 bacteria	 and	 therefore	 have	 a	 much	 broader	
		 201	
spectrum	of	lytic	activity.	For	example,	the	endolysin	LysAB2	has	been	reported	to	
effectively	 lyse	 Staphylococcus	 aureus,	 Bacillus	 subtilis,	 Streptococcus	 sanguis,	
Escherichia	 coli,	 Citrobacter	 freundii	 and	 Salmonella	 enterica,	 all	 in	 addition	 to	











































CD27L1-179	 Clostridium	difficile	 Yes	 Yes	 This	study	
Table	5.1	The	full	list	of	endolysin	expression	attempts	by	the	Purton	Group.	SPN9CC,	LoGT-




activity.	 This	 property	 is	 highly	 advantageous	 in	 some	 respects,	 yet	 highly	
problematic	in	others.	The	advantage	of	a	narrow	spectrum	antibiotic	is	that	only	the	
		 202	
target	 pathogenic	 bacteria	 are	 killed,	 while	 the	 commensal	 bacteria	 remain	
unharmed.	This	property	limits	the	development	of	resistance	and	the	opportunity	
for	pathogenic	re-colonisation.	The	disadvantage	is	that	a	precise	identification	of	the	
pathogen	 causing	 the	disease	must	 be	made	before	 the	 correct	 endolysin	 can	be	
prescribed	by	a	clinician,	and	a	distinct	endolysin	therapeutic	must	be	produced	for	
every	common	bacterial	infection.	
Unlike	 conventional	 antibiotics,	 where	 a	 single	 new	 drug	 discovery	 (such	 as	
teixobactin	 1.1.2.2)	 has	 the	 potential	 to	 treat	 hundreds	 of	 different	 bacterial	




















et	 al.	 2012).	 The	 ability	 of	 C.	 difficile	 to	 form	 spores,	 which	 can	withstand	 harsh	
conditions	and	antibiotics,	means	that	 it	 is	often	the	first	bacterium	to	re-colonise	
the	human	gut	after	treatment	with	broad-spectrum	antibiotics.	While	resistance	to	









domain.	 Removal	 of	 the	 C-terminal	 domain,	 to	 create	 CD27L1-179	 was	 found	 to	
improve	enzyme	activity	 and	marginally	 extend	 the	 lytic	 range	of	 the	endolysin	 –	
enabling	it	to	lyse	more	bacterial	species	(Mayer	et	al.	2008).		
The	 C.	 reinhardtii	 chloroplast	 has	 been	 successfully	 used	 to	 express	 two	 active	
endolysins	to	date,	Cpl-1	and	Pal,	both	of	which	are	specific	to	S.	pneumoniae.	To	
develop	the	C.	reinhardtii	chloroplast	as	a	platform	to	produce	endolysins,	and	given	
the	specific	nature	of	endolysins,	 it	 is	 important	to	show	production	of	endolysins	













chloroplast	 as	 described	 in	 2.3.2.	 An	HA	 tag	was	 added	 to	 the	 C-terminus	 of	 the	
protein	coding	sequence	 for	western	blot	detection,	and	SapI	and	SphI	 restriction	




to	E.	 coli	 growth,	 there	were	no	concerns	about	 its	 toxicity	during	cloning,	 so	 the	

















TN72_SR_cpl1-HA	 and	 TN72_SR_Control	 (as	 positive	 and	 negative	 controls,	
respectively)	 were	 prepared	 and	 separated	 by	 SDS-PAGE.	 After	 blotting	 to	 a	
nitrocellulose	 membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 the	 membrane	 was	
probed	with	 anti-HA	primary	 antibody,	 then	 incubated	with	 an	 IRDye®	 secondary	
antibody.	 Fluorescence	 was	 observed	 using	 the	 LiCor	 Odyssey®	 CLx	 system.	 The	
resulting	image	is	shown	in	Figure	5.2.	
	






































testing	 of	 the	 CD27L-containing	 crude	C.	 reinhardtii	 extract	 directly	 on	C.	 difficile	
using	the	Mayer	group’s	established	protocol.	
A	 turbidity	 reduction	 assay	 was	 performed	 as	 described	 in	 2.7.2.3.	 Two	
concentrations	of	 crude	extract,	 in	NaPi	buffer,	were	used:	 10	μg	and	50	μg.	 The	
purified	CD27L	was	provided	by	Dr	Mayer	and	used	as	a	positive	control.	It	was	an	
old	(2008)	NiNTA-purified	CD27L	sample	produced	in	E.	coli,	so	the	concentration	was	
































The	 recipient	 line	 TN72	 was	 transformed	 by	 the	 glass	 bead	 method	 using	 the	
pSRSapI_cd27l-StrepII	 plasmid.	 The	 resulting	 transformed	 line	 is	 represented	 in	
Figure	 5.5.	 Photosystem	 II	 functionality	 was	 restored	 by	 psbH	 and	 the	 resulting	
transformants	 were	 capable	 of	 growing	 phototrophically	 on	 minimal	 media.	
		 210	
Transformants	were	 shown	 to	 reach	a	homoplasmic	 state	 (Appendix	 L)	by	PCR	as	
described	in	2.3.17.	
	






described	 in	2.4.5,	 the	membrane	was	probed	with	 anti-StrepII	 primary	 antibody,	
then	incubated	with	IRDye®	secondary	antibody.	Fluorescence	was	observed	using	
the	 LiCor	Odyssey®	 CLx	 system.	 The	membrane	was	 then	 re-probed	with	 anti-HA	






















compared	 to	 a	 10	 μg	 protein	 standard.	 Quantification	 was	 performed	 using	 the	 LiCor	
Odyssey®	CLx	system,	after	which	the	standard	was	used	to	normalise	the	two	blots	and	the	
signal	from	the	21	kDa	bands	compared	in	a	bar	chart.		
The	 protein	 accumulation	 level	 of	 the	 HA-tagged	 protein	 appears	 to	 be	
approximately	 six	 times	 greater	 than	 the	 StrepII-tagged	 protein.	 However,	 as	
discussed	 in	 3.3.2.2.4.3,	 the	 difference	 observed	 is	 possibly	 due	 to	 the	 different	
















































buffer,	 suggesting	 that	 this	 enrichment	 has	 removed	many	 of	 the	 other	 proteins	














used.	 The	CD27L	 (E.	 coli)	 refers	 to	 a	purified	CD27L	 recombinant	protein	produced	by	Dr	
Mayer	 in	 E.	 coli,	 to	 act	 here	 as	 a	 positive	 control.	 This	 turbidity	 reduction	 assay	 was	
performed	by	Dr	Melinda	Mayer	at	Quadram	Institute	Bioscience,	Norwich,	UK.	
The	 data	 show	 convincing	 lysis	 of	 C.	 difficile	 cells	 in	 vitro,	 despite	 the	 fact	 that	
























The	 bacteriophage	 PA6	 is	 known	 to	 infect	 P.	 acnes	 and	 in	 2007	 its	 genome	was	
sequenced	(Farrar	et	al.	2007).	The	same	study	showed	that	PA6	was	able	to	infect	
32	different	P.	acnes	isolates	including	antibiotic	resistant	strains.	PA6	belongs	to	the	
























However,	 as	 seen	 in	 this	 thesis	 and	 elsewhere	 in	 the	 literature	 (e.g.	 Brault	 et	 al.	
































in	 2.3.17	 (Appendix	 N).	 Finally,	 the	 correct	 insertion	 was	 confirmed	 by	 DNA	
sequencing	as	in	2.3.18.	
5.3.3.2.4 Western	blotting	unable	to	confirm	accumulation	
To	 test	 for	 the	 accumulation	 of	Gp20	 in	C.	 reinhardtii,	whole	 cell	 preparations	 of	
TN72_WUCA2_gp20N-HA,	TN72_A_gp20-HA	(Taunt	2013),	and	TN72_SR_Control	(as	
two	negative	controls)	were	prepared	and	separated	by	SDS-PAGE.	After	blotting	to	
nitrocellulose	 membrane	 and	 blocking	 as	 described	 in	 2.4.5,	 the	 membrane	 was	
probed	 with	 anti-HA	 primary	 antibody,	 then	 incubated	 with	 IRDye®	 secondary	












early	 stages	of	development.	 Two	possible	 reasons	 for	 failure	 to	detect	Gp20	are	
either	the	failure	of	translation	or	instability	of	the	protein.	This	same	conclusion	was	
drawn	by	Taunt	(2013),	when	gp20	failed	to	express	in	C.	reinhardtii	on	a	previous	
occasion,	 with	 transcription	 issues	 and	 protein	 degradation	 being	 considered	 as	
unlikely	due	to	previous	literature	suggesting	that	transcripts	are	usually	present	in	
failed	 recombinant	 protein	 expression	 attempts	 (Rochaix	 2001),	 and	 endolysins	




known	 to	 be	 functional	 (See	 Cpl-1	 work	 3.3.2.2.1.4),	 it	 was	 supposed	 that	 the	









The	 failure	 to	 detect	 Gp20	 accumulation	 in	 the	 C.	 reinhardtii	 chloroplast	 after	
attempting	 several	 strategies	 led	 us	 to	 investigate	whether	 Gp20	was	 stable	 and	
active	when	expressed	as	a	recombinant	protein	in	E.	coli.	A	previous	investigation	
by	Taunt	(2013)	failed	to	observe	expression	of	Gp20	in	E.	coli	lines	transformed	with	
pASapI	 containing	 the	 gp20	 gene,	 believing	 a	 lack	 of	 optimisation	 of	 the	 atpA	
promoter/5’UTR	for	E.	coli	expression	to	be	responsible	(Wannathong	et	al.	2016).	
We	investigate	this	further	here,	as	if	protein	accumulation	can	be	achieved	in	E.	coli,	
then	 it	 suggests	 that	 the	 protein	 is	 likely	 to	 be	 stable	 in	 C.	 reinhardtii	 and	 that	
translation	 is	 likely	 to	 be	 the	 key	 issue	 in	 the	 failure	 to	 detect	 the	 recombinant	
protein.	
5.3.3.4.1 Expression	cassette	production	
The	gp20N-HA	gene	used	previously	 could	not	be	 reused	 for	 expression	 in	E.	 coli	
owing	to	the	presence	of	stop	codons	in	the	gene,	as	it	was	originally	designed	for	
use	 with	 the	 pWUCA2	 plasmid.	 A	 gp20	 gene	 with	 a	 C-terminal	 HA	 tag,	 codon	
optimized	 for	 Synechocystis	 expression	 in	 another	 project	 and	 synthesized	 by	
Integrated	 DNA	 technologies,	 was	 used	 as	 a	 template.	 Primers	were	 designed	 to	
introduce	a	NcoI	restriction	site	upstream	of	the	ATG.	A	BamHI	site	already	existed	




























‘Pressure	 cell’	 homogeniser	 (2.6.3),	 and	 centrifuged	 at	 5,000	 g	 for	 20	minutes	 to	
remove	 cell	 debris.	 The	 lysate	 was	 then	 filter	 sterilized	 using	 a	 0.22	 μm	 filter	 to	
remove	 any	 remaining	 viable	 E.	 coli	 cells.	 The	 same	 procedure	 was	 applied	 to	 a	















The	pellet,	 lysate	and	 filter	 sterilized	 lysate	were	prepared	and	separated	by	SDS-
PAGE.	After	blotting	to	nitrocellulose	membrane	and	blocking	as	described	in	2.4.5,	




















50	 μl	 of	 bacterial	 suspension	 and	 50	 μl	 of	 filter	 sterilized	 lysate	 or	 buffer	 were	
incubated	at	37	°C	for	0,	30,	60,	90,	120	or	150	minutes.	Three	10	μl	samples	were	
taken	 after	 the	 stated	 incubation	 time	 from	 each	 combination	 and	 spotted	 onto	








of	 the	 antimicrobial	 effect	 of	 Gp20	 difficult	 to	 measure.	 However,	 visually	 there	









as	 mentioned,	 the	 assay	 requires	 improvements	 for	 this	 conclusion	 to	 be	 more	
convincing.	Since	Taunt	(2013)	initially	investigated	gp20	expression	in	C.	reinhardtii,	
13	 other	 P.	 acnes	 targeting	 endolysins	 have	 been	 identified	 from	 other	
bacteriophages	(Marinelli	et	al.	2012).	These	putative	endolysins	display	remarkable	
sequence	 similarity,	 as	 do	 the	 whole	 bacteriophage	 genomes	 themselves.	 This	 is	
unusual	for	bacteriophage	and	unexpected,	as	usually	a	high	level	of	genetic	diversity	
exists	 amongst	 bacteriophage	 (Pride	 et	 al.	 2012).	 The	 differences	 that	 do	 occur	
between	endolysin	sequences	are	mostly	in	the	flexible	linker	region	separating	the	
two	domains.	This	significant	level	of	similarity	led	Marinelli	et	al.	(2012)	to	suggest	




This	 chapter	 has	 attempted	 to	 express	 two	 endolysins	 in	 the	 C.	 reinhardtii	
chloroplast.	 The	 first,	 CD27L,	 has	 been	 shown	 in	 the	 literature	 to	be	 active	when	
produced	in	E.	coli	and	tested	in	vitro	against	C.	difficile	(Mayer	et	al.	2008).	Here	we	
have	shown	that	CD27L	can	be	expressed	in	C.	reinhardtii	to	a	relatively	high	level	
















varied	 results.	 The	 StrepII-tagged	 CD27L	 protein	 appears	 to	 accumulate	 to	
significantly	lower	levels	than	the	HA-tagged	version	–	a	pattern	also	seen	with	Cpl-
1.	The	 finding	 that	StrepII-tagged	proteins	consistently	appear	 to	accumulate	 to	a	
lower	level	than	their	HA-tagged	counterparts	has	led	us	to	question	the	validity	of	
the	double-tagged	protein	standard	produced	in	3.3.1.2.6,	as	has	been	discussed	in	
more	 detail	 in	 3.3.2.2.4.3.	 For	 both	 this	 CD27L	 work	 and	 the	 Cpl-1	 work,	 it	 is	








while	we	were	 only	 able	 to	 use	 0.3	 μg	 per	well	 due	 to	 the	 diluted	 nature	 of	 the	
extract.	 This	 can	 be	 easily	 remedied	 by	 performing	 an	 ammonium	 sulphate	



















produced	 from	a	 codon-optimised	 gene	displayed	 significantly	 lower	 activity	 than	
that	produced	from	the	wild-type	nucleotide	sequence.	The	codon	optimised	version	




length	gene,	as	discussed	 in	5.3.2.1,	and	as	such	does	not	contain	 the	CBD	or	 the	
putative	internal	ribosome	binding	site	identified	by	Dunne	et	al.	(2016).	Dunne	et	al.	
(2016)	 noted	 that	 the	 free	 CBD	 of	 CD27L	 was	 not	 necessary	 for	 activity,	 but	







the	 chloroplast	 machinery,	 as	 although	 the	 chloroplast	 system	 does	 share	 many	
features	with	its	prokaryotic	ancestors,	translation	initiation	is	less	well	understood	
in	 the	 C.	 reinhardtii	 chloroplast.	 For	 example,	 although	 chloroplast	 16S	 rRNA	
molecules	 display	 a	 highly	 conserved	 anti-SD	 sequence	 near	 their	 3’	 end,	 the	








activity.	 Therefore,	 it	 may	 be	 more	 relevant	 to	 look	 at	 CTP1L,	 an	 endolysin	 that	
targets	Clostridium	tyrobutyricum,	and	was	shown	to	require	the	free	CBD	for	activity.	




the	most	helpful	next	 stage	 is	probably	more	advanced	 in	 vitro	 testing,	using,	 for	
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example,	a	triple-stage	chemostat	model	of	the	human	gut.	The	reason	for	this	is	that	
the	 most	 well-used	 animal	 model	 for	 CDI,	 the	 Syrian	 Hamster,	 is	 not	 fully	

















model	will	 doubtless	be	 required,	but	 the	use	of	 advanced	 in	 vitro	 testing	 should	
reduce	the	reliance	upon	these	and	 inform	more	precisely	which	tests	need	to	be	
carried	out.	
An	 interesting	 final	 consideration	of	C.	 reinhardtii-produced	CD27L	 is	 the	delivery	
mechanism.	 To	 date,	 C.	 reinhardtii-produced	 therapeutics	 have	 been	 considered	
most	viable	for	topical	applications	due	to	the	potential	cost	savings	made	by	using	a	
crude	 extract,	 on	 the	 assumption	 that	 a	 crude	 extract	 would	 not	 achieve	 FDA	







produced	 in	 C.	 reinhardtii	 to	 chickens	 and	 fish,	 and	 discussed	 the	 use	 of	 the	 C.	
reinhardtii	cell	as	a	delivery	capsule	(Rajakumar	2016).	While	this	concept	has	not	
been	 practically	 tested,	 Rajakumar	 (2016)	 suggests	 that	 the	 cell	 wall	 and	 the	
chloroplast	 of	 C.	 reinhardtii	 protect	 the	 therapeutic	 recombinant	 proteins	 from	
degradation	through	the	upper	levels	of	the	digestive	system,	enabling	them	to	reach	




The	Gp20	endolysin	has	been	problematic	 since	 recombinant	expression	was	 first	





protein	 is	 stable	 and	 active	 outside	 the	 P.	 acnes	 intracellular	 environment,	 the	
endolysin	was	expressed	 in	E.	coli.	 In	E.	coli	Gp20	accumulated	 to	high	 levels,	but	
colony	forming	unit	assays	using	a	crude	lysate	against	P.	acnes	failed	to	show	any	
activity.	Given	high	levels	of	interest	in	P.	acnes,	and	the	identification	of	at	least	14	
relevant	 putative	 endolysins,	 it	 does	 seem	 remarkable	 that	 no	 reports	 of	 a	





(2013)	 investigated	 whether	 translation	 initiation	 was	 the	 issue	 by	 creating	 a	




codon	 optimisation	 failed	 to	 solve	 the	 problem.	 Taunt	 (2013)	was	 also	 unable	 to	
detect	gp20	expression	in	E.	coli,	leading	to	a	suggestion	that	rapid	protein	turnover	
may	be	to	blame.	However,	strong	gp20	expression	in	E.	coli	was	described	earlier	in	






























The	 investigation	 requires	a	 suitable	positive	control,	 the	obvious	choice	being	an	
antibiotic	 such	 as	 erythromycin,	 the	 first	 line	 of	 treatment	 in	 a	 clinical	 setting	
(Zaenglein	 et	 al.	 2016).	 However,	 it	 would	 be	 preferable	 to	 have	 a	more	 specific	
antibacterial,	which	will	partially	confirm	that	the	bacteria	seen	are	indeed	P.	acnes	
and	not	a	contaminating	species.	The	peptide	adrenomedullin	is	secreted	by	human	
epithelial	 cells	 and	 has	 been	 demonstrated	 to	 have	 an	 antimicrobial	 effect	 upon	
several	microorganisms	 found	on	the	skin	and	respiratory	 tract,	but	 is	particularly	
effective	against	P.	acnes,	M.	luteus,	P.	gingivalis	and	H.	pylori	(Allaker	et	al.	1999).	It	
therefore	represents	a	narrower-spectrum	antimicrobial,	when	used	at	an	optimal	







environment,	 including	hydrolases	 and	proteases	 (Holland	 et	 al.	 2010),	 as	well	 as	
propionic	 and	 acetic	 acid	 which	 inhibit	 the	 growth	 of	 competing	 species	 (Wilson	
2005).	It	is	plausible	that	some	combination	of	these	factors	is	causing	the	endolysin	
to	denature	or	be	degraded	before	it	can	bind	and	lyse	the	cell	wall.	As	the	endolysins	




As	seen	earlier	 in	 this	chapter,	while	most	endolysins	consist	of	a	 simple	modular	
monomer,	others	such	as	PlyC	are	multimeric,	and	still	others	such	as	CTP1L	require	
oligomerisation	with	their	own	truncated	C-terminal	domain.	It	is	possible	that	the	
lack	of	 activity	 observed	with	Gp20	 is	 due	 to	 the	 requirement	 to	oligomerise	 like	
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CTP1L	 for	 full	 activity.	 Figure	 5.17	 shows	 a	 conserved	 methionine	 residue	 at	
approximately	position	193	which	could	be	an	internal	start	codon.	Also	at	position	
210	in	Figure	5.17	the	alternative	start	codon,	GTG,	codes	for	a	valine.	This	residue	is	
conserved	 as	 either	 a	 methionine	 or	 a	 valine	 in	 the	 other	 putative	 endolysins,	
however	an	analysis	of	the	nucleotide	sequence	is	required	to	identify	whether	this	
is	a	potential	internal	start	codon.	This	location	is	similar	to	that	observed	in	CTP1L	
and	CD27L	and	would	similarly	 result	 in	 the	synthesis	of	a	 free	CBD.	However,	no	
Shine	Dalgarno	consensus	can	be	seen	upstream	of	either	the	methionine-encoding	
ATG	or	valine-encoding	GTG	when	the	nucleotide	sequence	of	gp20	is	examined,	and	
analysis	 using	 the	 NCBI	 Open	 Reading	 Frame	 Finder	























this	 will	 make	 any	 difference.	 In	 this	 case	 the	 strategy	 needs	 to	 be	 to	 better	
understand	 why	 the	 endolysin	 is	 failing	 to	 express	 and	 attempting	 to	 solve	 any	
problems	with	activity.		
There	are	several	other	endolysins	which	would	be	interesting	to	express	in	the	C.	
reinhardtii	 chloroplast	 in	 the	 future.	 CTP1L	 is	 an	 interesting	 endolysin	 due	 to	 its	
requirement	 to	oligomerise	with	 its	 free	CBD,	but	 is	 also	 a	 commercially	 relevant	
endolysin,	 as	 it	 targets	 Clostridium	 tyrobutyricum.	 Clostridium	 tyrobutyricum	
contamination	can	lead	to	extensive	costs	in	the	cheese	production	industry	through	







drug	 synergies	 therapeutically,	 such	 as	 lower	 dosages,	 greater	 efficacy,	 and	
minimising	 the	 opportunity	 for	 resistance	 to	 occur.	 It	 would	 be	 interesting	 to	






as	 a	 stand-alone	 endolysin,	 as	 well	 as	 enabling	 an	 investigation	 into	 whether	 a	
synergistic	effect	can	be	observed	between	PlyCD	and	CD27L.		
As	 a	 final	 note	 on	 selecting	 future	 endolysins,	 one	 method	 might	 be	 termed	 a	





Streptococcus	pyogenes.	 It	 is	 therefore	conceivable	that	a	cocktail	of	 two	or	more	
endolysins	 targeting	S.	 aureus	 and	S.	 pyogenes	would	be	 a	 viable	 treatment.	 This	
particular	 example,	 as	 a	 topical	 application,	 would	 again	 be	 well	 suited	 to	 C.	























grows	 for	 protein	 therapeutics,	 such	 as	 monoclonal	 antibodies,	 hormones	 (e.g.	
human	insulin),	and	vaccines,	so	does	the	requirement	for	suitable	platforms	for	their	
recombinant	production.	As	discussed	in	1.3.1,	there	are	various	platforms	currently	





used	 to	 compare	 protein	 accumulation	 levels	 between	 different	 transgenic	 C.	
reinhardtii	 lines	 were	 investigated.	 The	 chapter	 highlights	 the	 limitations	 of	
comparing	protein	accumulation	levels	whilst	clonal	variation	appears	to	be	having	










first	 endolysin	 based	 therapies	 are	now	available	 (1.3.3.3).	 Chapter	 4	 investigates	
whether	 the	 activity	 of	 these	 endolysins	 can	 be	 improved	 against	 their	 target	







reinhardtii	 chloroplast.	 Several	 reasons	 for	 the	 failure	 of	 Cpl-1	 to	 dimerise	 were	
suggested,	 along	 with	 possible	 solutions,	 mostly	 revolving	 around	 the	 steric	
hindrance	 of	 the	 C-terminal	 epitope	 tag.	 Finally,	 the	 holin	 protein	 Cph-1	 was	
expressed	in	the	C.	reinhardtii	chloroplast.	However,	expression	quickly	ceased	and	
the	possible	reasons	for	this	were	discussed.	
Chapter	 5	 describes	 attempts	 at	 increasing	 the	 suite	 of	 endolysins	 that	 can	 be	
produced	in	the	C.	reinhardtii	chloroplast.	The	C.	difficile	targeting	endolysin,	CD27L,	
was	successfully	expressed	in	the	C.	reinhardtii	chloroplast	and	its	activity	against	C.	
difficile	 was	 demonstrated	 in	 vitro.	 Meanwhile,	 the	 P.	 acnes	 targeting	 endolysin,	
















investigate	 strategies	 for	 improving	 recombinant	 protein	 accumulation	 in	 the	 C.	
reinhardtii	chloroplast,	but	also	offers	an	opportunity	to	understand	what	leads	to	a	
very	high	or	 very	 low	expressing	 ‘clone’.	 In	order	 to	enable	 the	 investigation	 into	
subtler	methods	of	improving	recombinant	protein	accumulation,	in	3.4.2	we	suggest	
that	the	use	of	a	reporter	gene,	such	as	luciferase,	and	the	use	of	high-throughput	
techniques	 will	 enable	 ‘comparison-of-means’	 analysis.	 Advancements	 in	 whole	
genome	 sequencing,	 and	 importantly	 its	 falling	 cost,	 may	 eventually	 enable	 a	
methodical	whole	genome	analysis	of	high-expressing	clones	to	identify	mutations	or	
insertions	that	are	resulting	in	high	levels	of	protein	accumulation.	These	mutations	
might	 be	 affecting	 nuclear	 genes	 for	 chloroplast	 regulatory	 factors,	 proteases,	 or	
chaperones.	 These	 changes	 can	 then	be	 purposefully	 introduced	 alongside	 future	
transgenes,	thus	improving	C.	reinhardtii	as	a	protein	production	platform.	
The	endolysin	Cpl-1	was	the	main	focus	of	 investigation	 in	Chapter	4,	and	as	such	
much	 of	 the	 proposed	 future	 work	 was	 specific	 to	 this	 endolysin.	 However,	 the	
unexpected	 and	unexplained	 result	 that	Cph-1	 expression	was	 achieved	 and	 then	
ceased	 is	worthy	of	 further	 investigation.	Silencing	mechanisms,	while	common	 in	
nuclear	 transformations,	 have	 not	 previously	 been	 described	 in	 the	 chloroplast	
(Daniell	et	al.	2005).	It	is	therefore	important	to	understand	how	the	termination	of	









we	 can	 deduce	 the	 precise	 reason	 for	 this	 and	 attempt	 to	 ameliorate	 it.	 Codon	
optimisation,	 translation	 initiation,	 and	 epitope	 tag	 location	 have	 all	 been	
investigated	and	do	not	appear	 to	be	causing	 failure	of	expression.	Attempting	 to	
express	the	two	domains	of	the	endolysin	separately	may	shed	some	light	on	to	the	








in	 recombinant	 protein	 production,	 due	 to	 their	 frequent	 ability	 to	 provide	more	
consistent	 and	 higher	 final	 protein	 yields	 than	 endogenous	 regulatory	 elements	
(Gilman	 and	 Love	 2016).	 As	 discussed	previously	 in	 this	 thesis	 (3.1.2),	 chloroplast	

















controlling	 luciferase	 expression	 in	 the	 chloroplast.	 This	 false	 colour	 image	 illustrates	 the	
differences	in	luciferase	expression	under	different	5’UTRs.	Techniques	such	as	this	enable	
the	processing	and	expression	quantification	of	hundreds	of	C.	reinhardtii	colonies	in	a	very	






5’UTRs	 of	 endogenous	 genes	 and	 pave	 the	 way	 towards	 producing	 synthetic	
promoters	and	5’UTRs	that	dramatically	improve	protein	yields	as	well	as	providing	
consistent	levels	of	gene	expression.	The	work	by	Specht	&	Mayfield	(2013)	is	the	first	








the	 C.	 reinhardtii	 chloroplast	 (a	 cis-acting	 element),	 one	 could	 also	 modify	 the	
		 245	
regulatory	 elements	 themselves	 (trans-acting	 factors).	 Such	 an	 experiment	 was	
performed	by	Michelet	et	al.	(2011),	where	chloroplast	transgenes	were	shown	to	be	








to	 perform	 since	 targeted	 knock-outs	 of	 nuclear	 genes	would	be	possible.	 Rather	
than	knocking	out	trans-acting	elements	such	as	splicing	factors	which,	as	described,	
result	 in	 other	 undesirable	 phenotypes,	 CRISPR/Cas9	 could	 be	 used	 to	 knock-out	
other	 factors	 that	 indirectly	 control	 protein	 accumulation,	 such	 as	 chloroplast-
targeted	proteases.	The	ease	with	which	such	mutations	could	be	introduced	should	
quickly	enable	researchers	to	manipulate	the	chloroplast	environment	into	one	that	
is	 more	 amenable	 to	 recombinant	 protein	 accumulation	 without	 having	 large	
detrimental	effects	on	cell	physiology.		
6.2.1.3 Expression	of	novel	chaperones	





of	 the	 solution	 to	 improving	 protein	 accumulation,	 the	 quality	 of	 protein	 being	
produced	 is	 equally	 important,	 and	 disruption	 of	 proteases	 may	 have	 other	
detrimental	effects	upon	the	cell	(Ramundo	and	Rochaix	2014).		
While	recombinant	protein	yields	in	E.	coli	have	been	steadily	improved	over	the	past	
four	 decades,	 through	 a	 process	 of	 largely	 trial	 and	 error,	 we	 must	 attempt	 to	




investigation.	 Many	 chaperones	 are	 known	 to	 be	 expressed	 in	 the	 C.	 reinhardtii	
nucleus	 and	 targeted	 to	 the	 chloroplast	 to	 aid	 protein	 folding	 (Schroda	 2004).	
However,	some	novel	chaperones	may	have	specific	abilities	to	aid	in	the	folding	of	
certain	 recombinant	 proteins,	 and	 studies	 in	 E.	 coli	 have	 found	 that	 co-
overproduction	of	certain	chaperones	in	the	E.	coli	cytoplasm	have	aided	in	protein	







years	 of	 research	 behind	 it	 and	 its	 well-defined	 genetics,	 C.	 reinhardtii	 was	 the	
obvious	 initial	 candidate	 for	 proving	 the	 concept	 of	microalgae	 as	 a	 recombinant	
protein	 production	 platform.	 However,	 when	 it	 comes	 to	 scaling	 up	 microalgae	













low,	 hovering	 around	 5-8	mg	 L-1	culture	 volume	 (1.3.3.3),	 the	 potential	 for	 cheap	
cultivation	and	high	volumes	goes	some	way	towards	negating	this	issue.	In	contrast	















the	best	 option	 for	 commercial	 scale-up.	However,	 use	of	 high	 temperatures	 and	
extremophiles	 will	 require	 investigation	 into	 the	 thermostability	 of	 the	 proteins	
looking	to	be	produced,	and	will	not	be	suitable	for	all	products.	Furthermore,	the	




As	 with	 many	 emerging	 technologies,	 the	 adoption	 of	 endolysins	 as	 antibiotics	
depends	heavily	upon	the	status	of	the	existing	technology:	conventional	antibiotics.	
The	recent	discovery	of	a	new	antibiotic,	teixobactin,	and	the	novel	manner	in	which	
it	 was	 discovered	 (see	 1.1.2.2)	 may	 yet	 extend	 the	 ruling	 era	 of	 small	 molecule	
antibiotics.	While	the	discovery	of	new	antibiotics	is	clearly	a	good	thing,	it	is	vitally	
important	that	complacency	does	not	 limit	the	research	 into	endolysins	and	other	
antibiotic	 alternatives.	 Conventional	 antibiotics	 have	 clear	 disadvantages	 when	
compared	 to	endolysins	–	namely	 the	huge	selective	pressure	 they	exert	upon	all	
bacteria	 to	 form	 resistance,	 thus	 making	 us	 increasingly	 dependent	 upon	 new	
discoveries.	 It	 is	 of	 great	 importance,	 therefore,	 that	 research	 continues	 into	 the	
development	of	more	advanced	antibiotics	so	that	we	can	spread	our	reliance	across	





For	 full	 adoption	 of	 endolysins	 and	 replacement	 of	 conventional	 antibiotics,	 both	
much	 improved	 point-of-care	 diagnostics,	 and	 much	 more	 research	 into	 tackling	
Gram-negative	bacteria	are	 required.	Both	of	 these	are	 stumbling	blocks	 that	will	
take	 time	 and	 resources	 to	 overcome,	 but	 the	 final	 result	 will	 be	 a	 far	 superior	
solution	 to	 tackling	 bacterial	 infections.	 Furthermore,	 if	 endolysins,	 or	 any	 other	





Hypothetical	 conversations	with	 drug	 regulatory	 bodies	 and	 thought-experiments	
around	 the	 advantages	 of	 algae-based	 therapeutics	 are	 clearly	 important	 initial	
stages	 of	 developing	 a	 new	 recombinant	 protein	 platform,	 and	 currently	 more	
immediate	 issues	 such	 as	 low	 recombinant	 protein	 yields	 are	 preventing	
advancement	of	the	platform.	However,	to	perform	a	cost	comparison	of	microalgae	
and	 other	 platforms,	 and	 to	 establish	 the	 viability	 of	 the	 platform,	 it	 is	 vitally	
important	 to	 understand	 the	 extent	 to	 which	 drug	 regulatory	 bodies	 will	 look	
favourably	upon	proteins	produced	in	GRAS	organisms	such	as	C.	reinhardtii.	If	it	is	
the	 case	 that	 crude	 or	 enriched	 algal	 extracts	 can	 be	 approved,	 then	 this	will	 be	
enormously	encouraging	for	the	future	of	the	platform.	However,	 if	this	 is	not	the	
case,	 then	the	use	of	established	platforms	will	almost	always	be	more	 financially	
favourable.	 In	 this	 situation,	 the	 future	 of	 microalgae	 as	 recombinant	 protein	
production	 platforms	 must	 shift	 towards	 alternative	 markets,	 such	 as	 cosmetics,	
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Figure	 7.1	 Total	 protein	 staining	 of	 five	 technical	 repeats	 of	 TN72_SR_cpl1-HA	 and	

























Figure	 7.5	 Western	 blot	 analysis	 demonstrating	 the	 varying	 levels	 of	 HA-tagged	 protein	
accumulation	over	a	194	hour	culture	period.	
0 unidentified codons.
Nucleotide frequency:   A=29   U=45   G=15   C=10  X=0 
GC Content: 25.25%    1st letter GC: 36.36%    2nd letter GC: 27.27%    3rd letter GC: 12.12% 
 
Summary table:
Sequence length: 21279      Number of protein genes: 32      Total codons: 7093
0 unidentified codons.
Nucleotide frequency:   A=5880   U=7318   G=4106   C=3975  X=0 
GC Content: 37.98%    1st letter GC: 50.53%    2nd letter GC: 41.41%    3rd letter GC: 21.99% 
 






Amino acid | Codon | Number | Frequency per thousand
Phe UUU 1 30.3 Ser UCU 0 0.0 Tyr UAU 1 30.3 Cys UGU 0 0.0
UUC 0 0.0 UCC 0 0.0 UAC 1 30.3 UGC 0 0.0
Leu UUA 6 181.8 UCA 0 0.0 STOP UAA 1 30.3 STOP UGA 0 0.0
UUG 0 0.0 UCG 0 0.0 UAG 0 0.0 Trp UGG 0 0.0
Leu CUU 3 90.9 Pro CCU 0 0.0 His CAU 0 0.0 Arg CGU 0 0.0
CUC 0 0.0 CCC 0 0.0 CAC 0 0.0 CGC 0 0.0
CUA 0 0.0 CCA 0 0.0 Gln CAA 0 0.0 CGA 0 0.0
CUG 0 0.0 CCG 0 0.0 CAG 0 0.0 CGG 0 0.0
ile AUU 2 60.6 Thr ACU 1 30.3 Asn AAU 0 0.0 Ser AGU 1 30.3
AUC 2 60.6 ACC 0 0.0 AAC 0 0.0 AGC 0 0.0
AUA 0 0.0 ACA 2 60.6 Lys AAA 2 60.6 Arg AGA 0 0.0
Met AUG 1 30.3 ACG 0 0.0 AAG 0 0.0 AGG 0 0.0
Val GUU 2 60.6 Ala GCU 1 30.3 Asp GAU 0 0.0 Gly GGU 4 121.2
GUC 0 0.0 GCC 0 0.0 GAC 0 0.0 GGC 0 0.0
GUA 2 60.6 GCA 0 0.0 Glu GAA 0 0.0 GGA 0 0.0
GUG 0 0.0 GCG 0 0.0 GAG 0 0.0 GGG 0 0.0
Amino acid | Codon | Number | Frequency per thousand
Phe UUU 171 24.1 Ser UCU 147 20.7 Tyr UAU 87 12.3 Cys UGU 61 8.6
UUC 285 40.2 UCC 0 0.0 UAC 152 21.4 UGC 3 0.4
Leu UUA 544 76.7 UCA 144 20.3 STOP UAA 30 4.2 STOP UGA 0 0.0
UUG 5 0.7 UCG 9 1.3 UAG 2 0.3 Trp UGG 170 24.0
Leu CUU 152 21.4 Pro CCU 119 16.8 His CAU 23 3.2 Arg CGU 245 34.5
CUC 0 0.0 CCC 2 0.3 CAC 148 20.9 CGC 10 1.4
CUA 53 7.5 CCA 200 28.2 Gln CAA 218 30.7 CGA 2 0.3
CUG 9 1.3 CCG 13 1.8 CAG 10 1.4 CGG 0 0.0
ile AUU 343 48.4 Thr ACU 210 29.6 Asn AAU 83 11.7 Ser AGU 80 11.3
AUC 102 14.4 ACC 3 0.4 AAC 198 27.9 AGC 30 4.2
AUA 4 0.6 ACA 193 27.2 Lys AAA 240 33.8 Arg AGA 8 1.1
Met AUG 182 25.7 ACG 12 1.7 AAG 9 1.3 AGG 2 0.3
Val GUU 258 36.4 Ala GCU 433 61.0 Asp GAU 135 19.0 Gly GGU 586 82.6
GUC 0 0.0 GCC 9 1.3 GAC 115 16.2 GGC 24 3.4
GUA 261 36.8 GCA 173 24.4 Glu GAA 311 43.8 GGA 19 2.7

































CPOCv1 CPOCv2 cpl1-HA Total
N 3 3 3 9
∑X 0.115 0.4351 0.1253 0.6754
Mean 0.0383 0.145 0.0418 0.075
∑X2 0.0044 0.0632 0.0054 0.073
Std.Dev. 0.0035 0.0066 0.0075 0.0528
Result Details
Source SS df MS
Between-




Within-treatments 0.0002 6 0
Total 0.0223 8
The f-ratio value is 293.57558. The p-value is < 
.00001. The result is significant at p < .05.




CPOCv1 CPOCv2 cpl1-HA Total
N 3 3 3 9
∑X 0.3091 1.5043 0.2813 2.0948
Mean 0.103 0.5014 0.0938 0.2328
∑X2 0.0319 0.7607 0.0274 0.82
Std.Dev. 0.0038 0.0565 0.0221 0.2038
Result Details
Source SS df MS
Between-




Within-treatments 0.0074 6 0.0012
Total 0.3324 8
The f-ratio value is 131.77838. The p-value is 
.000011. The result is significant at p < .05.
		 279	
	




1 CPOCv1 CPOCv2 cpl1-HA Total
N 3 3 3 9
∑X 0.9648 1.4821 0.663 3.1099
Mean 0.3216 0.494 0.221 0.3455
∑X2 0.3137 0.8476 0.1472 1.3085
Std.Dev. 0.0411 0.2403 0.0178 0.171
Result Details
Source SS df MS
Between-
treatments 0.1144 2 0.0572
F = 
2.87208
Within-treatments 0.1195 6 0.0199
Total 0.2339 8
The f-ratio value is 2.87208. The p-value is .133348. 





1 CPOCv1 CPOCv2 cpl1-HA Total
N 2 2 2 6
∑X 0.894 0.9605 0.8009 2.6554
Mean 0.447 0.4803 0.4004 0.4426
∑X2 0.4022 0.4775 0.3281 1.2078
Std.Dev. 0.0505 0.1271 0.086 0.0807
Result Details
Source SS df MS
Between-
treatments 0.0064 2 0.0032
F = 
0.36948
Within-treatments 0.0261 3 0.0087
Total 0.0325 5
The f-ratio value is 0.36948. The p-value is .718715. 










CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.0837 0.2317 0.0405 0.3559
Mean 0.0418 0.1158 0.0202 0.0593
∑X2 0.0039 0.0268 0.0009 0.0316
Std.Dev. 0.02 0.0006 0.0059 0.0458
Result Details
Source SS df MS
Between-
treatments 0.0101 2 0.005
F = 
34.67033
Within-treatments 0.0004 3 0.0001
Total 0.0105 5
The f-ratio value is 34.67033. The p-value is 





CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.0713 0.1784 0.1145 0.3642
Mean 0.0357 0.0892 0.0573 0.0607
∑X2 0.0026 0.0159 0.0066 0.0251
Std.Dev. 0.0062 0.0057 0.0008 0.0244
Result Details
Source SS df MS
Between-
treatments 0.0029 2 0.0015
F = 
61.0499
Within-treatments 0.0001 3 0
Total 0.003 5
The f-ratio value is 61.0499. The p-value is .003714. 






CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.1001 0.2606 0.1458 0.5065
Mean 0.05 0.1303 0.0729 0.0844
∑X2 0.005 0.0356 0.011 0.0516
Std.Dev. 0.0003 0.0405 0.0193 0.0421
Result Details
Source SS df MS
Between-
treatments 0.0068 2 0.0034
F = 
5.09397
Within-treatments 0.002 3 0.0007
Total 0.0089 5
The f-ratio value is 5.09397. The p-value is .108497. 





CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.1803 0.2498 0.1553 0.5854
Mean 0.0901 0.1249 0.0776 0.0976
∑X2 0.0168 0.0313 0.0121 0.0603
Std.Dev. 0.0235 0.0102 0.0095 0.0251
Result Details
Source SS df MS
Between-
treatments 0.0024 2 0.0012
F = 
4.82318
Within-treatments 0.0007 3 0.0002
Total 0.0031 5
The f-ratio value is 4.82318. The p-value is .11554. 






CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 0.9233 0.8594 0.3558 2.1385
Mean 0.4617 0.4297 0.1779 0.3564
∑X2 0.4288 0.3714 0.0634 0.8636
Std.Dev. 0.0505 0.0458 0.0095 0.1424
Result Details
Source SS df MS
Between-
treatments 0.0966 2 0.0483
F = 
30.59972
Within-treatments 0.0047 3 0.0016
Total 0.1014 5
The f-ratio value is 30.59972. The p-value is 





CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 1.1899 1.1952 0.3528 2.7379
Mean 0.595 0.5976 0.1764 0.4563
∑X2 0.7086 0.7301 0.0634 1.5021
Std.Dev. 0.0245 0.126 0.0342 0.2248
Result Details
Source SS df MS
Between-
treatments 0.2351 2 0.1175
F = 
20.00184
Within-treatments 0.0176 3 0.0059
Total 0.2527 5
The f-ratio value is 20.00184. The p-value is 







CPOCv1 CPOCv2 Cpl-1 Total
N 2 2 2 6
∑X 1.4863 1.4019 0.6651 3.5533
Mean 0.7431 0.7009 0.3326 0.5922
∑X2 1.1065 0.9986 0.222 2.327
Std.Dev. 0.0445 0.1261 0.0284 0.211
Result Details
Source SS df MS
Between-
treatments 0.204 2 0.102
F = 
16.38062
Within-treatments 0.0187 3 0.0062
Total 0.2227 5
The f-ratio value is 16.38062. The p-value is 


































































The	stop	codons	are	highlighted	 in	red.	The	HA	tag	 is	highlighted	 in	purple.	SapI	and	SphI	
restriction	sites	are	indicated	by	blue	arrows.	
TG GTA TGC TCT TCA ATG GCA TAC CCA TAT GAT
GTA CCT GAC TAT GCT GTT CGT TAT ATT CCA GCT
GCT CAT CAC TCA GCA GGT TCT AAC AAT CCT GTT
AAT CGT GTA GTA ATT CAT GCA ACA TGT CCA GAT
GTA GGA TTT CCT AGT GCT AGC CGT AAA GGT CGT
GCT GTT TCA ACT GCT AAT TAC TTC GCA TCA CCA
TCT AGT GGT GGT AGC GCT CAC TAT GTG TGT GAC
ATT GGA GAA ACA GTA CAA TGT TTA TCT GAA AGT
ACT ATT GGA TGG CAC GCA CCA CCA AAC CCT CAT
TCA TTA GGT ATT GAA ATT TGT GCT GAT GGT GGT
TCT CAT GCT AGC TTT CGT GTG CCT GGT CAC GCA
TAT ACA CGT GAA CAA TGA TTA GAT CCA CAA GTT
TGG CCA GCT GTT GAA CGT GCT GCA GTA TTA TGT
CGT CGT TTA TGT GAC AAA TAC AAT GTA CCT AAA
CGT AAA TTA TCA GCT GCT GAC TTA AAA GCA GGT
CGT CGT GGT GTT TGT GGT CAT GTT GAT GTA ACT
GAC GCT TGA CAC CAA AGC GAT CAT GAT GAT CCA
GGA CCA TGG TTT CCT TGG GAC AAA TTC ATG GCT
GTT GTA AAC GGT GGT AGC GGT GAC AGC GGA GAA
TTA ACA GTT GCA GAT GTA AAA GCT TTA CAC GAT
CAA ATT AAA CAA TTA TCA GCA CAA TTA ACT GGT
AGC GTG AAC AAA TTA CAT CAC GAT GTT GGT GTT
GTA CAA GTG CAA AAC GGT GAC TTA GGA AAA CGT
GTA GAC GCT TTA AGC TGG GTG AAA AAT CCA GTG
ACT GGA AAA TTA TGA CGT ACA AAA GAT GCT TTA
TGG TCT GTT TGG TAT TAT GTA TTA GAA TGT CGT
AGC CGT TTA GAT CGT TTA GAA AGC GCT GTA AAT












NAME SEQUENCE NOTES 
Flank1 GTCATTGCGAAAATACTGGTGC 
Primers for general 

























Primers for the site-
directed mutageneis of 











Cpl1_BssHII.F CAGGCAATTTGCTTACACCTTT Primers to introduce a 
BssHII restriction site 
into Cpl-1 Cpl1_BssHII.R TTAAGATAAGCGCGCTACATCC 
cpl1_C45S.F ACATATTTAAATCCATCATTATCAGCTC 
Primers to remove and 
introduce cysteine 





cd27l.F TGGTATTGCTCTTCAATGAAAATTTGTATTACT Primers for the 
replacement of the HA 




gp20_NcoI.F CGTATACCCATGGTGCGTTA Primers to introduce an 
NcoI restriction site to 
gp20 gp20.R GATTGCGGATCCTTATTAGGC 
	
